KR100614216B1 - Pharmaceutical composition containing substituted alkano hydroxamic acid as an active ingredient - Google Patents

Abstract

The present invention relates to a pharmaceutical composition containing substituted alkano hydroxamic acid as an active ingredient, and by using the substituted alkano hydroxamic acid derivative of the present invention having an excellent effect of reducing TNFα concentration, Not only can provide pharmaceutical compositions for the treatment or prevention of eggplant inflammatory, infectious, immune or malignant diseases, but also can be used for the veterinary treatment of mammals other than humans in need of suppression or prevention of TNFα production. There is.

Alkanohydroxysamic acid, inflammation, immunity, TNFα, TNFα mediated

Description

Pharmaceutical composition containing substituted alkano hydroxamic acid as an active ingredient

The present invention relates to a pharmaceutical composition containing substituted alkanohydroxysamic acid as an active ingredient.

This application is part CIP of United States Patent Application No. 08 / 903,975, filed January 31, 1997.

Tumor necrosis factor α (tumor necrosis factor α) is a cytokine released mainly by monocytes in response to various immunostimulators. When administered to an animal or human body, it causes an acute phase response that is similar to inflammation, fever, cardiovascular effects, bleeding, blood clotting and reactions in acute infections or shock conditions. Excessive or unregulated production of TNFα is associated with many disease states. These include endotoxomia and / or toxic shock syndrome {Tracey et al., Nature 330 , 662-664 (1987) and Hinshaw et al., Circ Shock 30 , 279-292 (1990)}. ; Cachexia {Dezube et al., Lancet , 335 (8690), 662 (1990)} and Adult Respiratory Distress Syndrome (ARDS), and lung respiration of ARSD patients in adult respiratory syndrome TNFα concentrations in excess of 1,2000 pg / mL were detected at launch (Millar et al., Lancet 2 (8665), 712-714 (1989)). Systemic infusion of recombinant TNFα also results in a generally seen change in ARSD {Ferrai-Baliviera et al., Arch. Surg . 124 (12), 1400-1405 (1989)}.

TNFα appears to be associated with bone resorption diseases, including arthritis. When leukocytes are activated, they will give rise to bone resorption activity and data suggest that TNFα contributes to this activity {Bertolini et al ., Nature 319 , 516-518 (1986) and Johnson et al ., Endocrinology 124 (3), 1424-1427 (1989)}. In addition, TNFα has been known to promote osteoclast formation and activation in association with inhibition of osteoblast function, thereby inhibiting bone formation and promoting bone resorption in vitro and in vivo through stimulation. Although TNFα is associated with many bone resorption diseases, including arthritis, the most indispensable link to the disease is the association between malignant tumors associated with hypercalcemia and TNFα production by tumors or host tissues { Calci . Tissue Int . (US) 46 (Suppl.), S3-10 (1990)}. In graft versus host response, an increase in serum TNFα levels is associated with major complications following acute allogeneic bone marrow transplantation (Holler et al., Blood, 75 (4), 1011-1016 (1990)).

Cerebral malaria is a fatal hyperacute neurological syndrome associated with high blood levels of TNFα, the most serious complication of malaria. Serum TNFα levels are directly correlated with the severity of the disease and the prognosis of patients with acute malaria infections [Grau et al., N. Engl . J. Med . 320 (24), 1586-1591 (1989)}.

Macrophage-induced angiogenesis TNFα is known to be mediated by TNFα. Leibovich et al. Nature , 329 , 630-632 (1987)} show that TNFα induces capillary formation in the rat cornea and the development of chorioallantoic membranes in chicks at very low doses in vivo, while TNFα induces inflammation, wound healing and tumors. It is suggested that it is a candidate agent for inducing angiogenesis in growth. TNFα production is also associated with incurable diseases, in particular induced tumors {Ching et al., Brit. J. Cancer , (1955) 72 , 339-343, and Koch, Progress in Medical Chemistry , 22 , 166-242 (1985)}.

TNFα is also associated with the field of chronic pulmonary inflammatory disease. Sedimentation of silica particles leads to silicosis, which leads to progressive respiratory failure due to fiber reactions. Antibodies against TNFα completely block rat lung fibrosis {Pignet et al., Nature, 344 : 245-247 (1990)}. High levels of TNFα production in serum and macrophages have been demonstrated in animal models of silica and asbestos that induced fibrosis (Bissonnette et al., Inflammation 13 (3), 329-339 (1989)). Alveolar macrophages in patients with pulmonary sarcoidosis have been known to spontaneously release large amounts of TNFα as compared to normal donor macrophages [Baughman et al., J. Lab. clin . Med . 115 (1), 36-42 (1990).

TNFα is also associated with an inflammatory response involving reperfusion, called reperfusion injury, and is a major cause of tissue damage after loss of blood flow [Vedder et al., PNAS 87 , 2643-2646 (1990)}. . TNFα also alters the properties of endothelial cells, down-regulating the expression of thrombomodulin, inhibits the anticoagulant protein C pathway, and causes tissue factor pro-coagulant activities. ) Have a variety of precoagulant activities such as (Sherry et al., J. Cell Biol . 107 , 1269-1277 (1988)}. TNFα has pro-inflammation activity, which appears to act as a mediator of tissue damage in some serious diseases, including myocardial infarction, seizures and circulatory shock, with early production of TNFα (during the early stages of inflammation). TNFα-induced expression of adhesion molecules, such as intracellular adhesion molecules (ICMs) or endothelial lymphocyte adhesion molecules (ELAMs), appears to be particularly important {Munro et al., Am. J. Path . 135 (1), 121-132 (1989)}.

TNFα inhibition by monoclonal anti-TNFα antibodies has been shown to be beneficial in rheumatoid fractures {Elliot et al., Int . J. Pharmc . 1995 17 (2), 141-145}. High concentrations of TNFα are associated with Crohn's disease and have been shown to be of clinical benefit through treatment with TNFα antibodies {von Dullermen et al., Gastroenterology , 1995 109 (1), 129-135}.

Moreover, TNFα is now known as a potent activator of retroviral replication, including the activity of HIV-1. Duh et al., Proc . Nat. Acad . Sci . 86 , 5974-5978 (1989); Poll et al., Proc . Nat. Acad . Sci . 87 , 782-785 (1990); Monto et al., Blood 79 , 2670 (1990); Clouse et al., J. Immunol . 142 , 431-438 (1989); Poll et al., AIDS Res. Hum. Retrovirus , 191-197 (1992)}. AIDS results from T lymphocyte infection of the Human Immunodeficiency Virus (HIV). At least three types or strains of HIV have been identified, HIV-1, HIV-2 and HIV-3. As a result of HIV infection, T-cell mediated immune responses are impaired and those infected exhibit severe opportunistic infections and / or rare tumors. T lymphocytes must be activated for HIV to enter T lymphocytes. Other viruses, such as HIV-1 and HIV-2, infect T lymphocytes after T cells are activated and protein expression and / or replication of these viruses is mediated or sustained by T cell activity. Once activated T lymphocytes are infected with HIV, T lymphocytes must remain activated to enable HIV gene expression and / or HIV replication. Cytokines, specifically TNFα, are involved in T-cell mediated HIV protein expression and / or viral replication activated by playing a role in maintaining T lymphocyte activity. Thus, interference with cytokine activity, in particular inhibition and inhibition of cytokine production, such as TNFα, helps to limit T lymphocyte maintenance caused by HIV infection in HIV infected people.

Monocytes, macrophages, and related cells such as kupffer cells and glial cells are also involved in maintaining HIV infection. Like T cells, these cells are target cells for viral replication, and the extent of viral replication depends on the active state of these cells. {Rosenberg et al., The Immunopathogenesis of HIV INfection , Advances in Immunology, 57 (1989)} Cytokines such as TNFα have been shown to activate HIV replication in monocytes and / or macrophages {Poli et al. Proc . Natl . Acad . Sci. 87 , 782-784 (1990)}, therefore, interfering with or inhibiting cytokine production or activity helps limit HIV progression as in T cells. Further studies have shown that TNFα is a common factor in HIV activation in vitro and the mechanism of activity through nuclear regulatory proteins found in the cytoplasm of cells is clearly known (Osborn, et al., PNAS 86 , 2336-2340). ). This evidence shows that decreased TNFα synthesis has an antiviral effect on HIV infection, through decreased transcription and thus reduced virus production.

AIDS viral replication of latent HIV in T cells and macrophage lines can be induced by TNFα {Folks et al ., PNAS 86 , 2336-2340 (1989)}. The molecular mechanism of viral induced activity is known to be due to the ability of TNFα to activate gene regulatory protein (NFκB) found in the cytoplasm of cells, which promotes HIV replication by binding to viral regulatory gene sequences (LTRs). et al ., PNAS 86 , 2365-2368 (1989)}. It is known that TNFα in AIDS associated with cachexia raises serum TNFα and spontaneously produces TNFα in high concentrations in peripheral blood mononuclear cells of patients {Wright et al. J. Immunol . 141 (1), 99-104 (1988)}. TNFα is associated with various roles of other viral infections, such as cytomegalia virus (CMV), influenza virus, adenovirus and herpes family virus.

Nuclear Factor κB (NFκB) is a pleiotropic trnascriptional activator (Lenardo, et al. Cell 1989, 58, 227-29). NFκB is associated with transcriptional activators in a variety of diseases and inflammatory conditions, but is not limited to TNFα, but is believed to regulate cytokine concentrations and to be active in HIV transcription (Dbaibo, et al . J. Biol . Chem) . . 1993, 17762-66;... Duh et al Proc Natl Acad Sci 1989, 86, 5974-78;.. Bachelerie et al, Nature 1991, 350, 709-12;.. Boswas et al, J. Acquired Immune Deficiency Syndrome 1993, 6, 778-786; .. Suzuki et al Biochem And Biophys Res Comm 1993, 193, 277-83;....... Suzuki et al Biochem And Biophys Res Comm 1992, 189, 1709-15 ;..... Suzuki et al Biochem Mol Bio Int 1993, 31 (4), 693-700;. Shakhov et al 1990, 171. 35-47;..... and Staal et al Proc Natl Acad Sci USA 1990, 87, 9943-47). Therefore, inhibition of NFκB binding can modulate the transcription of cytokine genes, and is useful for inhibiting many disease states through such regulation and other mechanisms. Compounds disclosed herein can inhibit the activity of NFκB in the nucleus, so rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, other arthritic conditions, septic shock ), Sepsis, endotoxic shock, graft versus host disease, wasting, Crohn's disease, ulcerative colitis, multiple sclerosis It is useful in the treatment of various diseases including, but not limited to sclerosis, systemic lupus erythrematosis, ENL in leprosy in leprosy, opportunistic infections in HIV, AIDS, and AIDS. Are affected by mutual feedback loops As mentioned above, the compounds of the present invention affect TNFα and NFκB concentrations.

Many cellular functions are mediated by adenosine 3 ', 5'-cyclic monophosphate (cAMP) concentrations. Such cellular functions can cause inflammatory diseases, including asthma, inflammation and other conditions (Lowe and Cheng. Drugs of the Future , 17 (9), 799-807, 1992). Increasing cAMP in inflammatory leukocytes has been shown to inhibit their activity and thereby the release of inflammatory mediators including TNFα and NFκB. In addition, increasing cAMP relaxes airway smooth muscle. It has been found that phosphodiesterase controls cAMP concentration through hydrolysis and that inhibitors of phosphodiesterase increase cAMP concentration.

Therefore, decreasing the TNFα concentration and / or increasing the cAMP concentration is a useful therapeutic strategy for the treatment of many inflammatory, infectious, immune or malignant diseases. These include perishable shock, sepsis, endotoxin shock, hemodynamic shock and sepsis syndrome, post ischemic reperfusion injury, malaria, mycobacterial infection ), Meningitis, psoriasis, congestive heart failure, fibrotic disease, cachexia, graft rejection, cancer, autoimmune disease, opportunistic infections in AIDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, other arthritic conditions, Crohn's disease ), Ulcerative colitis, multiple sclerosis, systemic lupus erythrematosis, ENL in leprosy in leprosy, radiation da mage), and hyperoxic alveolar injury, but previous efforts to inhibit TNFα effects have resulted from the use of steroids such as dexamethasone and prednisolone to polyclones. The use ranged from the use of antibodies and monoclonal antibodies {Beutler et al., Science 234 , 470-474 (1985); WO 92/11383).

Inhibition of matrix metalloproteinase (MMP) has been associated with TNF inhibition (Mohler et al., Nature, 370, 218-220 (1994)). MMP or matrixin is a family like zinc endopeptidase that is secreted and bound to the membrane, which plays an important role in tissue degradation either physiologically or pathologically [Yu et al., Drugs & Aging, 1997, (3): 229-244; Wojtowicz- Praga et al., Int . New Drugs, 16: 61-75 (1997)}. These enzymes are extracellular matrix, including fibrillar and non-fibrillar collagen, fibronectin, laminin and membrane glycoproteins that make up the cell membrane. The component can be decomposed. There is usually a delicate balance between cell division, interstitial synthesis and interstitial degradation (under cytokine control), growth factors, and interstitial interactions. However, in pathological illness this balance can be broken. Diseases associated with undesirable MMP levels include, but are not limited to, tumor metastasis, invasion and growth, rheumatoid arthritis, osteoarthritis, osteopenias such as osteoporosis, periodontitis, gingivitis, and epidermal or stomach ulcers Do not.

Increasing MMP activity has been found in a wide range of cancers [Denis et al., Invest. New Drugs, 15: 175-185 (1987)}, as in TNF, MMPs are believed to be involved in the stage of invasion of angiogenesis and tumor variation.

The present invention provides a pharmaceutical composition comprising alkanohydroxamic acids substituted with imido and amido, a method for reducing TNF α concentration in a mammal by administering the compound, and the derivative as an active ingredient. For that purpose.

The present invention is based on the discovery that certain types of non-polypeptide compounds described in more detail herein reduce the concentration of TNFα, increase the concentration of cAMP, and inhibit phosphodiesterase. .

In particular, the invention (a) A compound of general formula (I):

Where R ¹ And R ² are each independently hydrogen, lower alkyl (lower alkyl) or, R ¹ and R ² together with the carbon atoms common to the respective bonded, o - phenylene group (phenylene), o - naphthylene group (o- naphtylene ), Or cyclohexene-1,2-diyl, unsubstituted or nitro, cyano, trifluoromethyl or carbetoxy groups (carbetoxy), carbometoxy, carbopropoxy, carbopropoxy, acetyl, carbamoyl, carbamoyl, acetoxy, carboxy, hydroxy hydroxy, amino, alkylamino, dialkylamino, acylamino, alkyl having 1 to 10 carbon atoms, alkoxy having 1 to 10 carbon atoms ) And 1 to 4 substituents each independently selected from the group consisting of halogen groups (halo) ubstituents);

R ³ has a nitro group, a cyano group, a trifluoromethyl group, a carbetoxy group, a carbopropoxy group, an acetyl group, a carbamoyl group, an acetoxy group, a carboxy group, a hydroxyl group, an amino group, and having 1 to 10 carbon atoms Alkyl group, alkoxy group having 1 to 10 carbon atoms, alkylthio having 1 to 10 carbon atoms, benzyloxy, cycloalkoxy having 3 to 6 carbon atoms, C ₄ -C _{From the} group consisting of a ₆ -cycloalkylidenemethyl group (C ₄ -C ₆ -cycloalkylidenemethyl), a C ₃ -C ₁₀ -alkylidenemethyl group (C ₄ -C ₆ -alkylidene methyl), an indanyloxy group and a halogen group A phenyl group substituted with 1 to 4 substituents selected;

R ⁴ is hydrogen, an alkyl group having 1 to 6 carbon atoms, a phenyl group or a benzyl group;

R ^{4 '} is hydrogen or an alkyl group having 1 to 6 carbon atoms;

R ⁵ is —CH ₂ —, —CH ₂ —CO, —CO—, —S0 ₂ —, —S— or —NHCO—;

n is 0, 1 or 2;

And

( b ) an acid addition salt of the compound containing a nitrogen atom capable of receiving a proton. .

Unless defined otherwise, the term alkyl group refers to a monovalent saturated saturated branched or straight hydrocarbon chain having 1 to 8 carbon atoms. Representative alkyl groups are methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, secondary butyl group (sec-butyl), tertiary butyl group (tert-butyl). An alkoxy group refers to an alkyl group which is bonded to the rest of the molecule through the oxygen atom of the ether. Representative alkoxy groups are methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group and tert-butoxy group.

Compounds of formula I are used under the supervision of a qualified professional to inhibit the undesirable effects of TNFα and phosphodiesterases. These compounds can be administered orally, rectally or parenterally, alone or in combination with other therapeutic agents such as antibiotics, steroids and the like.

The compounds of the present invention may also be used locally for the treatment or prevention of local diseases mediated or aggravated by excessive TNFα production, including infections caused by viral infections and herpes virus or viral conjunctivitis, psoriasis, atopic dermatitis, and the like. There is the same.

The compounds of the present invention can also be used for the veterinary treatment of humans as well as many other mammals in need of inhibition or prevention of TNFα production. In animals, TNFα mediated diseases in need of therapeutic or prophylactic treatment include such disease states, in particular viral infections. For example, as well as lentiviruses, feline immunodeficiency virus, equine infectious anaemia virus, caprine arthritis virus, visna virus And the madi virus.

The present invention also relates to the treatment of MMP inhibitory compounds and their composition, diseases associated with undesirable production or activity of MMPs. These compounds can inhibit connective tissue breakdown and are used for the treatment and prevention of diseases including connective tissue breakdown. This includes but is not limited to tumor variation, invasion and growth and osteopenias such as rheumatoid arthritis, osteoarthritis, osteoporosis, periodontitis, gingivitis and corneal epidermal ulcers or gastric ulcers.

The present invention therefore further encompasses a therapy consisting of an effective dosage of an MMP inhibitory compound of Formula I and a compound according to Formula I.

Compounds of formula I can be readily obtained by the reaction of carboxylic acids of the general formula:

Wherein R ¹ , R ² , R ³ , R ⁵ and n together with hydroxylamine hydrochloride or alkoxyamine hydrochloride in the presence of a coupling agent, are each defined in formula (I). Same as The reaction is generally effected by an inert solvent such as tetrahydrofuran in an inert atmosphere such as nitrogen. It can be done at room temperature. When the reaction is substantially finished, the product can be easily separated off by simply adding water.

Compounds of general formula (II) used as intermediates in the present invention are disclosed in US Pat. No. 5,605,914. In short, these intermediates can be obtained through amino acid reactions of the general formula:

The general formula R ¹⁴ is a hydroxy group or an acid anhydride (acid anhydride), N- carboxylic chopping toksiyi imide (N-carbethoxyimide), di-aldehydes (dialdehyde) or o - protection, such as bromo direction acid (o -bromo aromatic acid) It is a protecting group.

The protecting group used here is generally not found in the final therapeutic compound but is found at some stage of the deliberately induced synthesis, in order to protect the group that could otherwise be altered in the course of chemical manipulation. These protecting groups are removed at a later stage of the synthesis and therefore compounds with these groups are of primary importance as chemical intermediates (although some derivatives exhibit biological activity). Therefore, the exact structure of the protection group is not important. Many reactions to the formation and removal of such protective groups are described in "Protective Groups in Organic Chemistry", Plenum Press, London and New York, 1973; Green, Th. W. "Protective Groups in organic Synthesis", Wiley, New York, 1981; "The Peptides", Vol. I, Schroder and Lubke, Academic Press, London and New York, 1965; It is described in a number of standard studies, including "Methoden der organischen Chemie", Houben-Weyl, 4th Edition, Vol. 15 / I, Georg Thieme Verlag, Stuttgart 1974, and disclosed by reference.

In any of the above reactions, nitro compounds having nitro groups which are converted to amino groups by catalytic hydrogenation can be used. Optionally, the protected amino group may be removed to yield the corresponding amino compound. The amino group is formed under mild conditions, in particular benzyloxycarbonyl, formyl or a tertiary alkanoyl such as carbonyl group, especially pivaloyl, at the 1- or α-position. Amide groups using an acyl group that can be selectively removed from a branched lower alkanoyl group, a lower alkanoyl group substituted with a carbonyl group such as trifluoroacetyl at the α position, for example trifluoroacetyl Can be protected as.

Compounds of formula I have at least one chirality center (designated as "*") and can exist as optical isomers. Deastereomers as well as racemates and individual isomers of these isomers are within the scope of the present invention when there are two polarization centers. The vilates can be used as they are or can be mechanically separated into these individual isomers, such as by chromatography with a chiral absorber. Optionally, the individual isomers can be prepared in the form of chiral or 10-camphorsulfonic acid, camphoric acid, α-bromocamphoric acid, methoxyacetic acid, tartaric acid. Can be chemically separated from the mixture by forming salts with chiral acids or salts such as enantiomers such as diacetyltinic acid, malic acid, pyrrolidone-5-carboxylic acid and the like. Then, one or two of the dissolved salts are liberated and the process is optionally repeated to obtain one or two optical isomers with an optical purity of at least 95% where substantially no other salts are present.

The present invention also relates to non-toxic acid addition salts of physiologically acceptable Formula I compounds. These salts include, without limitation, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulphonic acid, acetic acid, tartaric acid, lactic acid, succinic acid (succinic acid), citric acid, malic acid, maleic acid, sorbic acid, sorbic acid, aconitic acid, salicylic acid, phthalic acid, embonic acid And those derived from organic and inorganic acids such as enanthic acid.

The present invention also includes physiologically acceptable non-toxic salts of the compounds of formula I with bases such as sodium salts, potassium salts, aluminum salts and the like.

The first preferred subgroup encompasses compounds of the general formula:

R ⁴ in the general formula is hydrogen or alkyl having 1 to 4 carbon atoms;

R ^{4 '} is hydrogen or alkyl having 1 to 4 carbon atoms;

R ⁵ is C═O or CH ₂ ;

R ⁶ and R ⁷ are each independently hydrogen, nitro group, cyano group, trifluoromethyl group, carbetoxy group, carbomethoxy group, carbopropoxy group, acetyl group, carbamoyl group, acetoxy group, carboxy group, Hydroxy group, amino group, alkyl group having 1 to 4 carbon atoms, alkoxy group having 1 to 4 carbon atoms, cycloalkoxy having 3 to 6 carbon atoms, bicycloalkyl group having 6 to 10 carbon atoms ( bicyclo alkyl, indanyloxy, C ₄ -C ₆ -cycloalkyl idenemethyl group, C ₃ -C ₆ -alkylidenemethyl group and halogen group;

R ⁸ , R ⁹ , R ¹⁰ are each independently hydrogen, nitro group, cyano group, trifluoromethyl group, carbetoxy group, carbomethoxy group, carbopropoxy group, acetyl group, carbamoyl group, acetoxy group, carboxyl group, hydroxy Period, amino group, alkylamino group, dialkylamino group, acylamino group, acylamino group, alkyl group having 1 to 10 carbon atoms, alkoxy group having 1 to 10 carbon atoms, and halogen group;

n is 1.

Among the compounds of formula IV, R ⁸ , R ⁹ R ¹⁰ and R ¹¹ are each hydrogen, a halogen group, an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, and R ⁸ , R ⁹ , R ¹⁰ , R ¹¹ It is more preferred that one of is amino, hydroxy or methyl and the remaining is hydrogen.

More preferred subgroups encompass compounds of the general formula

R ^{4 ′} in the formula is hydrogen or alkyl having 1 to 4 carbon atoms;

R ⁵ is C═O or CH ₂ ;

R ¹² and R ^{13 '} are each independently an alkoxy group having 1 to 4 carbon atoms, a cycloalkoxy having 3 to 6 carbon atoms, a C ₄ -C ₆ -cycloalkylidenemethyl group, C _{A 3} -C ₆ -alkylidenemethyl group and an indanyloxy group;

R ⁸ , R ⁹ , R ¹⁰ and R ¹¹ are each independently hydrogen, nitro group, cyano group, trifluoromethyl group, carbetoxy group, carbomethoxy group, carbopropoxy group, acetyl group, carbamoyl group, acetoxy group , Carboxyl group, hydroxy group, amino group, alkylamino group (alkylamino), dialkylamino group, dialkylamino group, acylamino group, alkyl group having 1 to 10 carbon atoms, alkoxy group having 1 to 10 carbon atoms and halogen group ;

R ⁸ , R ⁹ in compounds of Formula V R ¹⁰ and R ¹¹ are each hydrogen, a halogen group, an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, and R ⁸ , R ⁹ More preferably, one of R ¹⁰ and R ¹¹ is an amino or hydroxy group and the other is hydrogen.

More preferred compounds are 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (1-oxoisoindolinyl) propionamide, 3- (3-ethoxy-4-methoxyphenyl ) -N-methoxy-3- (1-igoisoindolinyl) propionamide, N-benzyloxy-3- (3-ethoxy-4-methoxyphenyl) -3-phthalimidopropionamide, N-benzyl Oxy-3- (3-ethoxy-4-methoxyphenyl) -3- (3-nitrophthalimido) propionamide, N-benzyloxy-3- (3-ethoxy-4-methoxyphenyl) -3- (1-oxoisoindolinyl) propionamide, 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3-phthalimidopropionamide, N-hydroxy-3- (3 , 4-dimethoxyphenyl) -3-phthalimidopropionamide, 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (3-nitrophthalimido) propionamide, N -Hydroxy-3- (3,4-dimethoxyphenyl) -3- (1-oxoisoindolinyl) propionamide, 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3 -(4-methylphthalimido) propy Amide, 3- (3-cyclopentyloxy-4-methoxyphenyl) -N-hydroxy-3-phthalimidopropionamide, 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy- 3- (1,3-dioxo-2,3-dihydro-1H-benzo [f] isoindol-2-yl) propionamide, N-hydroxy-3- {3- (2propoxy) -4 -Methoxyphenyl} -3-phthalimidopropionamide, 3- (3-ethoxy-4-methoxyphenyl) -3- (3,6-difluorophthalimido) -N-hydroxypropionamide, 3- (4-aminophthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide, 3- (3-aminophthalimido) -3- (3 -Ethoxy-4-methoxyphenyl) -N-hydroxypropionamide, N-hydroxy-3- (3,4-dimethoxyphenyl) -3- (1-oxoisoindolinyl) propionamide, 3- (3-cyclopentyloxy-4-methoxyphenyl) -N-hydroxy-3- (1-oxoisoindolinyl) propionamide, N-benzyloxy-3- (3-ethoxy-4-methoxyphenyl ) -3- (3-nitrophthalimido) propionamide It includes.

Oral dosage forms include tablets, capsules, dragees, and similar forms, including compressed pharmaceutical dosage forms containing 1-100 mg / mL per unit dose. Isotonic saline solutions containing 20-100 mg / mL can be used for parenteral administration, including intramuscular, intrathecal, intravenous, and intraarterial route administration. Rectal administration may also be effective through the use of suppositories formulated from traditional carriers such as cocoa butter.

Accordingly, the pharmaceutical composition consists of one or more compounds of formula I in association with at least one pharmaceutical acceptable carrier, diluent or excipient. In preparing such compositions, the active ingredients are usually enclosed with a carrier which may be mixed or diluted by excipients, or may be in the form of capsules or small sachets. When the excipient acts as a stoning agent, it will be a solid, semisolid or liquid substance which acts as a vehicle, carrier, medium of the active ingredient. Thus, the composition may contain tablets, pills, powders, elixirs, suspensions, emulsions, solutions, syrups, soft and hard gelatin capsules, suppositories, sterile It may be in the form of injectable solutions and sterile packaged powders. Examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium silicate ), Microcrystalline cellulose, polyvinylpyrrolidinone, cellulose, water, syrup, methyl cellulose, and the composition includes lubricants such as talc, magnesium stearate and mineral oil. , Wetting agents, emulsifiers, suspension agents, preservatives such as methyl groups and propylhydroxy ben zoate, and sweeteners such as seasonings.

The composition may preferably be formulated in unit dosage form, wherein the physiologically suitable unit dose is a discrete unit or a small amount of single unit previously scheduled to be administered to a human or other mammal in one or multiple dosage regimens. Each unit contains an amount of active substance calculated to produce the desired therapeutic effect in association with a suitable pharmaceutical excipient. The composition may be formulated to provide immediate, sustained or delayed release of the active agent after administration to a patient using well known technical procedures.

Enzyme-linked immunosorbent assay (ELISA) for TNFα can be performed in a general manner. PBMCs are isolated from normal donors by Ficoll-Hypaque density centrifugation. Cells are cultured in RPMI supplemented with 10% AB + serum, 2 mM L-glutamine, 100 U / mL penicillin and 100 mg / mL streptomycin. The drug is dissolved in dimethylsulfoxide (Sigma Chemical) and further dilution occurs at supplemented RPMI. The final dimethyl sulfoxide concentration in the PBMC suspension, with or without drug, is 0.25 wt%. Drugs are assayed at half-log dilutions starting at 50 mg / mL. Drugs are added to PBMC (10 ⁶ cells / mL) in 96 well plates 1 hour before LPS. PBMCs (10 ⁶ cells / mL) with or without drugs are stimulated by treatment with 1 mg / mL LSP taken from Salmonella minnesota R595 (List Biological Labs, Campbell, CA). The cells are then incubated at 37 ° C. for 18-20 hours. The supernatant is frozen immediately at -70 ° C (no more than four days) until TNFα concentration results are taken immediately and assayed or assayed. TNFα concentration in the supernatant is determined by the human TNFαELISA kit (ENDOGEN, Boston, MA) according to the manufacturer's instructions.

Phosphodiesterases can be determined in a general model. For example, using Hill and Mitchell's method, U937 cells of human promonocytic cells grow to 1 × 10 ⁶ cells / mL and are collected by centrifugation. Cell pellets of 1 × 10 ⁹ cells are washed in phosphate buffer saline and then frozen or cold homogenization buffer (20 mM Tris-HCl, pH 7.1, 3 mM) at -70 ° C for later purification. 2-mercaptoethanol, 1 mM magnesium chloride, 0.1 mM ethylene, glycol-bis- (beta-aminoethyl ether) -N, N, N ', N' tertacetic acid (EGTA), 1 μM phenyl Dissolves immediately in Phenylmethylsulfonylfluoride (PMSF), 1 μg / mL leupetin. The cells are homogenized 20 strokes in a Dounce homogenizer and centrifugation yields a supernatant containing the cytosolic fraction of the cytoplasm. The supernatant is then loaded onto a Sephacryl S-20 column equilibrated in homogenization buffer. Phosphodiesterase is eluted in homogenization buffer at a rate of approximately 0.5 mL / min and fraction is assayed for phosphodiesterase activity-/ + rolipram.

Phosphodiesterase assays are performed based on the process described by Hill and Mitchell. This assay is performed in 100 μl total volume containing various concentrations of Celgene compounds, 50 mM Tris-HCl, pH 7.5, 5 mM magnesium chloride, 1 μM cAMP, where 1% is ³ H cAMP. The reaction is incubated at 30 ° C. for 30 minutes and terminated by boiling for 2 minutes. The amount of phosphodiesterase IV containing the extract used in this experiment is predetermined so that the reaction is within the linear range and consumes less than 15% of the total substrate. After completion of the reaction, the specimen was cooled at 4 ° C. and then treated with 10 μl 10 mg / mL venom venom at 30 ° C. for 15 minutes. Unused substrates are removed by adding 200 μl of quaternary ammonia ion exchange resin (AG1-X8, BioRad) for 15 minutes. The specimen is then spun at 3000 rpm for 5 minutes and 50 μl of the aqueous phase is taken for counting. The score of each data is repeated twice and the activity is expressed as a percentage of the control. The IC 50 of the compound is determined from the minimum dose response curve of at least three independent experiments.

Hereinafter, the characteristics of the present invention will be described in more detail with reference to Examples, but the scope of the present invention is not limited to the above Examples.

Example  One

3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxy -3- (1- Oxoisoindolinyl ) Propionamide

3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (1-oxoisoindolinyl) propionic acid (15.0 g, 42.7 mmol) and N in tetrahydrofuran (50 mL) under nitrogen. A mixture of, N'-carbonyldiimidazole (7.27 g, 55.5 mmol) was stirred at room temperature for 2 hours. To the resulting solution was added hydroxylamine hydrochloride (3.86 g, 55.5 mmol). The resulting suspension was stirred for 18 hours. Water (150 mL) was added to this suspension and stirring continued for 1 hour. The suspension is filtered and the solid washed with water (5 × 30 mL) and ether (2 × 20 mL), then 3- (3-ethoxy-4-methoxy as a white solid (13.0 g, 82% yield). Phenyl) -N-hydroxy-3- (1-oxoisoindolinyl) propionamide to dry overnight in a vacuum oven (60 ° C., <1 torr): mp, 167-168 ° C .; ¹ H NMR (DMSO-d ₆ ) δ 1.29 (t, J = 6.9 Hz, 3H, C H ₃ ), 2.81-2.86 (m, 2H, C H ₂ ), 3.72 (s, 3H, C H ₃ ) , 3.96-4.04 (m, 2H, C H ₂ ), 4.13 (d, J = 17.5 ㎐, 1H, CH H ), 4.54 (d, J = 17.5 ㎐, 1H, NCH H ), 5.73 (t, J = 7.9 μs, 1H, NC H ), 6.84-6.92 (m, 3H, Ar), 7.43-7.68 (m, 4H, Ar), 8.83 (br s, 1H, O H ), 10.61 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ 14.68, 35.04, 46.22, 51.20, 55.44, 63.73, 111.85, 112.19, 119.21, 122.78, 123.43, 127.83, 131.29, 131.85, 132.27, 141.67, 147.85, 148.42, 165.99. . Anal. Calcd for C ₂₀ H ₂₂ N ₂ O ₅ : C, 64.85; H, 5.99; N, 7.56. Found: C, 64.73; H, 6. 17; N, 7.36.

In a similar manner, 3- (3-cyclopentyloxy-4-methoxyphenyl) -N-hydroxy-3- (4-methylphthalimido) propionamide is 3- (3-cyclopentyloxy-4-meth Hydroxyl of oxyphenyl) -N-hydroxy-3- (4-methylphthalimido) propionic acid (2.0 g, 4.7 mmol), carbonyldiimidazole (842 mg, 5.19 mmol) and tetrahydrofuran (10 mL) Prepared from amine hydrochloride (426 mg, 6.13 mmol). The product was a white solid (1.34 g, 65% yield): mp, 112.0-116.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.56-1.87 (m, 8H, C ₅ H ₈ ), 2.47 (s, 3H, C H ₃ ), 3.09 (d, J = 7.8 Hz, 2H, C H ₂ ), 3.70 (s, 3H, C H ₃ ), 4.71-4.74 (m, 1H, OC H ), 5.65 (t, J = 7.8 ㎐, 1H, NC H ), 6.88 (br s, 2H, Ar), 7.01 (br s, 1H, Ar), 7.61-7.76 (m, 3H, Ar), 8.79 (br s, 1H, O H ), 10.59 (br s, 1H, N H ); ¹³ C NMR (DMSOd ₆ ) δ 21.34, 23.53, 32.19, 34.29, 50.12, 55.54, 79.56. 112.06, 114.10, 119.65, 123.05, 123.53, 128.62, 131.27, 131.60, 134.92, 145.58, 146.72, 149.13, 166.03, 167.64, 167.75; Anal. Calcd for C ₂₄ H ₂₆ N ₂ O ₅ 1.2 H ₂ O: C, 62.65; H, 6. 22; N, 6.09. Found: C, 62.56; H, 6. 12; N, 5.87.

Example  2

3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxy -3- (4- Methylphthalimido ) Propionamide

A. 3-Amino-3- (3-ethoxy-4-methoxyphenyl) propionic acid (3.00 g, 12.5 mmol) and 4-methylphthalic anhydride of acetic acid (2.13 g, 12.5 mmol, 95%) The stirred solution of is warmed to reflux under nitrogen for 18 hours. The mixture was cooled to room temperature. The solvent was separated to yield an oil in vacuo. The resulting oil was stirred for 30 minutes with ethyl acetic acid (10 mL), hexane (10 mL) and water (30 mL). The suspension obtained was then filtered. The solid was washed with water (3 × 10 m) and hexanes (3 × 10 mL), then 3- (3-ethoxy-4-methoxyphenyl)-as a white solid (3.4 g, 71% yield). Dried overnight in a vacuum oven (60 ° C., <1 torr) to yield 3- (4-methylphthalimido) propionic acid: mp, 134.0-136.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.31 (t, J = 6.9 ㎐, 3H, C H ₃ ), 3.23 (dd, J = 6.7, 16.5 ㎐, 1H, CH H ), 3.50 (dd, J = 9.2, 16.5 ㎐, 1H, CH H ), 3.72 (s, 3H, C H ₃ ), 3.97 (q, J = 6.9 ㎐, 2H, C H ₂ ), 5.58 (dd, J = 6.7, 9.1 ㎐, 1H , NC H ), 6.90-6.95 (m, 2H, Ar), 7.01 (br s, 1H, Ar), 7.61-7.76 (m, 3H, Ar), 12.4 (br s, 1H, O H ); ¹³ C NMR (DMSO-d ₆ ) δ14.65, 21.32, 36.09, 50.04, 55.45, 63.72, 111.79, 112.15, 119.29, 123.08, 123.58, 128.51, 131.35, 131.49, 134.95, 145.63, 147.75, 148.53, 167.67. , 171.72; Anal. Calcd for C ₂₁ H ₂₁ NO ₅ : C, 65.79; H, 5.52; N, 3.65. Found: C, 65.46; H, 5.57; N, 3.31.

B.3- (3-ethoxy-4-methoxyphenyl) -3- (4-methylphthalimido) propionamide is a 3- (3-ethoxy- which is a white solid (1.34 g, 65% yield) 3- (3-ethoxy-4-methoxyphenyl) -3- (4-methylphthalimide to yield 4-methoxyphenyl) -N-hydroxy-3- (4-methylphthalimido) propionic acid Fig. 1) From propionic acid (2.40 g, 6.26 mmol), N, N'-carbonyldiimidazole (1.12 mg, 6.91 mmol) and tetrahydrofuran (8 mL) hydroxylamine hydrochloride (530 mg, 7.62 mmol) Prepared by the procedure of example 1: mp, 180.0-181.5 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.31 (t, J = 6.9 ㎐, 3H, C H ₃ ), 2.49 (s, 3H, C H ₃ ), 3.09 (d, J = 7.9 ㎐, 2H, C H ₂ ), 3.97 (q, J = 7.0 μs, 2H, C H ₂ ), 5.65 (t, J = 7.9 μs, 1H, NC H ), 6.89 (br s, 2H, Ar), 7.01 (br s, 1H, Ar), 7.61-7.74 (m, 3H, Ar), 8.78 (br s, 1H, O H ), 10.57 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ14.67, 21.33, 34.31, 50.14, 55.45, 63.72, 111.75, 112.33, 119.61, 123.03, 123.52, 128.63, 131.32, 131.61, 134.88, 145.54, 145.54, 147.67, 148.52 , 167.62, 167.73; Anal. Calcd for C ₂₁ H ₂₂ N ₂ O ₅ : C, 63.31; H, 5.57; N, 7.03. Found: C, 63.29; H, 5.69; N, 6.86.

Example  3

3- (3- Cyclopentyloxy -4- Methoxyphenyl ) -N- Hydroxy -3- Phthalimidopropionamide

A. sodium carbonate (1.20 g, 11.3 mmol) of 3-amino-3- (3-cyclopentyloxy-4-methoxyphenyl) propionic acid (3.00 g, 10.8 mmol) with acetonitrile, water (30 mL) was stirred for 15 minutes at room temperature under nitrogen. To the resulting solution was added N-ethoxycarbonylphthalimide (2.36 g, 10.8 mmol). This mixture was stirred at room temperature for 18 hours. Most of the solvent was separated in vacuo. To produce a suspension, hydrochloric acid (6N) was added to this solution until the pH of the solution was below 1 and stirring continued for 1 hour. The suspension is filtered and the solid washed with water (2 × 10 mL), then 3- (3-cyclopentyloxy-4-methoxyphenyl) -3- as a white solid (3.0 g, 68% yield) -3- Dry overnight in a vacuum oven to yield phthalimidopropionic acid (60 ° C., <1 torr): mp, 168.0-169.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.55-1.88 (m, 8H, C ₅ H ₈ ), 3.27 (dd, J = 6.9, 16.5 μs, 1H, CH H ), 3.51 (dd, J = 8.9, 16.5 ㎐, 1H, CH H ), 3.71 (s, 3H, CH ₃ ), 4.71-4.75 (m, 1H, C H ), 5.61 (dd, J = 6.9, 8.8 ㎐, 1H, NC H ), 6.87- 6.95 (m, 2H, Ar), 7.03 (br s, 1H, Ar), 7.81-7.91 (m, 4H, Ar), 12.4 (br s, 1H, O H ); ¹³ C NMR (DMSO-d ₆ ) δ23.51, 32.14, 32.17, 36.07, 50.08, 55.52, 79.57, 112.15, 113.97, 119.39, 123.17, 131.09, 131.19, 134.66, 146.77, 149.16, 167.67, 171.72; Anal. Calcd for C ₂₃ H ₂₃ NO ₅ : C, 67.47; H, 5. 66; N, 3.42. Found: C, 67.21; H, 5. 46; N, 3.45.

B. 3- (3-cyclopentyloxy-4-methoxyphenyl) -N-hydroxy-3-phthalimidopropionamide is a 3- (3-ethoxy- which is a white solid (1.45 g, 93% yield) 3- (3-cyclopentyloxy-4-methoxyphenyl) -3-phthalimidopropionic acid (to yield 4-methoxyphenyl) -N-hydroxy-3- (4-methylphthalimido) propion amide 1.50 g, 3.67 mmol), hydroxylamine hydrochloride (308 mg, 4.43 mmol) of N, N'-carbonyldiimidazole (653 mg, 4.03 mmol) and tetrahydrofuran (5 mL) of Example 1 Prepared by the procedure: mp, 169.0-171.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.54-1.85 (m, 8H, C ₅ H ₈ ), 3.09 (d, J = 7.9 kHz, 2H, C H ₂ ), 3.69 (s, 3H, C H ₃ ), 4.70-4.72 (m, 1H, C H ), 5.67 (t, J = 7.9 ㎐, 1H, NC H ), 6.87 (br s, 2H, Ar), 7.01 (br s, 1H, Ar), 7.79 -7.87 (m, 4H, Ar), 8.78 (br s, 1H, 0 H ), 10.58 (1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ23.51, 32.17, 34.23, 50.19, 55.53, 79.57, 112.08, 114.16, 119.69, 123.11, 131.16, 131.20, 134.59, 146.73, 149.17, 166.01, 167.63; Anal. Calcd for C ₂₃ H ₂₄ N ₂ O ₅ : C, 65.08; H, 5. 70; N, 6.60. Found: C, 64.73; H, 5. 60; N, 6.53.

Example  4

N- Hydroxy -N- methyl -3- (3- Ethoxy -4- Methoxyphenyl ) -3- (1- Oxoisoindolinyl ) Propionamide

N-hydroxy-N-methyl-3- (3-ethoxy-4-methoxyphenyl) -3- (1-oxoisoindolinyl) propionamide is N as a white solid (650 mg, 61% yield) 3- (3-ethoxy-4-meth) to yield -hydroxy-N-methyl-3- (3-ethoxy-4-methoxyphenyl) -3- (1-oxoisoindolinyl) propionamide N-methyl-hydroxyl of oxyphenyl) -3- (1-oxoisoindolinyl) propionic acid (1.0 g, 2.8 mmol), carbonyldiimidazole (500 mg, 3.1 mmol) and tetrahydrofuran (10 mL) Prepared by the procedure of Example 1 from amine hydrochloride (300 mg, 3.5 mmol): mp, 122.0-124.5 ° C .; ¹ H NMR (CDCl ₃ ) δ1.43 (t, J = 7.0 ㎐, 3H, C H ₃ ), 3.14 (s, 3H, NC H ₃ ), 3.37-3.48 (m, 2H, C H ₂ ), 4.02 (q, J = 7.0 ㎐, 2H, C H ₂ ), 4.11 (d, J = 17.2 ㎐, NCH H ), 4.51 (d, J = 17.2 ㎐, 1H, NCH H ), 5.95 (dd, J = 6.5 , 10.9 μs, 1H, NC H ), 6.83-6.97 (m, 3H, Ar), 7.34-7.55 (m, 3H, Ar), 7.81 (d, J = 7.1 μs, 1H, Ar), 9.44 (br s , 1H, 0 H ); ¹³ C NMR (CDCl ₃ ) δ 14.71, 36.04, 38.11, 48.14, 52.36, 55.95, 64.52, 111.42, 112.42, 119.45, 122.95, 123.63, 128.06, 130.57, 131.88, 141.72, 148.65, 149.18, 170.00; Anal. Calcd for C ₂₁ H ₂₄ N ₂ O ₅ : C, 65.61; H, 6. 29; N, 7.29. Found: C, 65.56; H, 6. 26; N, 7.09.

Example  5

3- (3- Cyclopentyloxy -4- Methoxyphenyl ) -N- Hydroxy -3- (4- Methylphthalimido )- Propionamide

3- (3-Cyclopentyloxy-4-methoxyphenyl) -N-hydroxy-3- (4-methylphthalimido) -propionamide is a 3- (3-solid, which is a white solid (1.34 g, 65% yield). 3- (3-cyclopentyloxy-4-methoxyphenyl) to yield 3-cyclopentyloxy-4-methoxyphenyl) -N-hydroxy-3- (4-methylphthalimido) -propionamide Hydroxylamine of -N-hydroxy-3- (4-methylphthalimido) -propionic acid (2.0 g, 4.7 mmol), carbonyldiimidazole (842 mg, 5.19 mmol) and tetrahydrofuran (10 mL) Prepared by the procedure of Example 1 from hydrochloride (426 mg, 6.13 mmol): mp, 112.0-116.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.56-1.87 (m, 8H, C ₅ H ₈ ), 2.47 (s, 3H, C H ₃ ), 3.09 (d, J = 7.8 Hz, 2H, C H ₂ ), 3.70 (s, 3H, CH ₃ ), 4.71-4.74 (m, 1H, OC H ), 5.65 (t, J = 7.8 ㎐, 1H, NC H ), 6.88 (br s, 2H, Ar), 7.01 (br s, 1H, Ar), 7.61-7.76 (m, 3H, Ar), 8.79 (br s, 1H, O H ), 10.59 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ 21.34, 23.53, 32.19, 34.29, 50.12, 55.54, 79.56. 112.06, 114.10, 119.65, 123.05, 123.53, 128.62, 131.27, 131.60, 134.92, 145.58, 146.72, 149.13, 166.03, 167.64, 167.75; Anal. Calcd for C ₂₄ H ₂₆ N ₂ O ₅ 1.2 H ₂ O: C, 62.65; H, 6. 22; N, 6.09. Found: C, 62.56; H, 6. 12; N, 5.87.

Example  6

3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxy -3- (1,3- Dioxo -2,3- Dehydro -1H- Benzo [f] isoindole -2 days) Propionamide

A. 3- (3-Ethoxy-4-methoxyphenyl) -N-hydroxy-3- (1,3-dioxo-2,3-dihydro-1H-benzo [f] isoindole-2- I) propionic acid is 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (1,3) as a grayish white solid (4.9 g, 93% yield) according to Example 2A 3-amino-3- (3-ethoxy-4-methoxyphenyl) propionic acid (3.00) to yield -dioxo-2,3-dihydro-1H-benzo [f] isoindol-2-yl) propionic acid g, 12.5 mmol) and 2,3-naphthalenedicarboxylic anhydride (2.59 g, 12.5 mmol) of acetic acid (20 mL): mp, 193.0-194.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.32 (t, J = 6.9 ㎐, 3H, C H ₃ ), 3.34 (dd, J = 7.1,16 ㎐, 1 H, CH H ), 3.57 (dd, J = 8.9, 16 μs, 1H, CH H ), 3.74 (s, 3H, C H ₃ ), 4.02 (q, J = 6.9 μs, 2H, C H ₂ ), 5.71 (dd, J = 7.8 μs, 1H, NC H ), 6.91-6.98 (m, 2H, Ar), 7.09 (br s, 1H, Ar), 7.74-7.78 (m, 2H, Ar), 8.23-8.27 (m, 2H, Ar), 8.50 (br s, 2H, Ar), 12.5 (br s, 1H, O H ); ¹³ C NMR (DMSO-d ₆ ) δ14.62, 36.03, 50.28, 55.43, 63.71, 111.79, 112.28, 119.45, 124.55, 126.87, 129.27, 130.24, 131.24, 135.03, 147.74, 148.57, 167.29, 171.75; Anal. Calcd for C ₂₄ H ₂₁ NO ₅ : C, 68.73; H, 5.05; N, 3.34. Found: C, 68.59; H, 5. 25; N, 3.17.

B. 3- (3-Ethoxy-4-methoxyphenyl) -N-hydroxy-3- (1,3-dioxo-2,3-dihydro-1H-benzo [f] isoindole-2- Yl) propionamide is 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (1,3-dioxo- which is a greyish white solid (1.6 g, 77% yield) 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (1 to yield 2,3-dihydro-1H-benzo [f] isoindol-2-yl) propionamide , 3-dioxo-2,3-dihydro-1H-benzo [f] isoindol-2-yl) propionic acid (2.00 g, 4.77 mmol), N, N'-carbonyldiimidazole (889 mg, 5.48 mmol) and tetrahydrofuran (8 mL) of hydroxylamine hydrochloride (419 mg, 6.03 mmol) were prepared by the procedure of Example 1: mp, 197.0-199.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.33 (t, J = 7.0 Hz, 3H, C H ₃ ), 3.11-3.28 (m, 2H, C H ₂ ), 3.73 (s, 3H, C H ₃ ) , 4.00 (q, J = 7.0 kPa, 2H, C H ₂ ), 5.79 (t, J = 7.8 kPa, 1H, NC H ), 6.87-7.09 (m, 2H, Ar), 7.10 (br s, 1H, Ar), 7.74-7.78 (m, 2H, Ar), 8.23-8.27 (m, 2H, Ar), 8.49 (br s, 2H, Ar), 8.85 (br s, 1H, O H ), 10.66 (br s , 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ14.69, 34.27, 50.42, 55.45, 63.73, 111.73, 112.45, 119.82, 124.50, 127.04, 129.28, 130.26, 131.20, 135.05, 147.69, 148.58, 166.07, 167.30; Anal. Calcd for C ₂₄ H ₂₂ N ₂ O ₅ : C, 66.35; H, 5. 10; N, 6.45. Found: C, 66.22; H, 5. 24; N, 6.08.

Example  7

3- (3- Ethoxy -4- Methoxyphenyl ) -N- Methoxy -3- (1- Oxoisoindolinyl ) Propionamide

N, N'-carbonyldiimine of methylene chloride (30 mL) under 3- (3-ethoxy-4-methoxyphenyl) -N-methoxy-3- (1-oxoisoindolinyl) propionic acid and nitrogen A mixture of dozol (250 mg, 1.54 mmol) was stirred at room temperature for 30 minutes. To this solution 0-methylhydroxylamine hydrochloride (175 mg, 2.09 mmol) was added followed by 1-methyl piperidine (0.26 ml, 2.14 mmol). The mixture was stirred at room temperature for 2 hours and then heated for 14 hours to reflux. The cooled reaction mixture was washed with hydrochloric acid (1N, 25 mL), saturated sodium bicarbonate (25 mL), brine (25 mL) and dried over sodium carbonate and sodium sulfate. . Removal of the solvent in vacuo gave a solid which was stirred with ether (10 mL) for 30 minutes. This suspension is filtered and the solid is a white solid (360 mg, 67% yield). Wash with ether (2 × 10 mL) to yield 3- (3-ethoxy-4-methoxyphenyl) -N-methoxy-3- (1-oxoisoindolinyl) propionamide: mp, 138.0 -139.5 ° C .; ¹ H NMR (CDCl ₃ ) δ1.41 (t, J = 6.9 Hz, 3H, C H ₃ ), 2.95 (dd, J = 4.6,14.5 Hz, 1H, CH H ), 3.53 (dd, J = 11.2, 14.5 ㎐, 1H, CH H ), 3.62 (s, 3H, C H ₃ ), 3.84 (s, 3H, C H ₃ ), 4.02 (q, J = 6.9 ㎐, 2H, C H ₂ ), 4.23 (d , J = 17.1 μs, 1H, NCH H ), 4.46 (d, J = 17 μs, 1H, NCH H ), 5.49 (dd, J = 4.4,10.3 μs, 1H, NC H ), 6.78-6.99 (m, 3H, Ar), 7.27-7.51 (m, 3H, Ar), 7.78 (dd, J = 7.4 Hz, 1H, Ar), 10.08 (br s, 1H, N H ); ¹³ C NMR (CDCl ₃ ) δ 14.66, 37.52, 49.48, 54.94, 59.1, 64.01, 64.41, 111.37, 112.12, 119.26, 122.75, 123.54, 128.04, 131.68, 132.58, 141.44, 148.56, 149.15, 167.81, 169.47 Anal. Calcd for C ₂₁ H ₂₄ N ₂ O ₅ C, 65.61; H, 6. 29; N, 7.29. Found: C, 65.23; H, 6.52; N, 6.88.

Example  8

N- Benzyloxy -3- (3- Ethoxy -4- Methoxyphenyl ) -3- Phthalimidopropionamide

N-benzyloxy-3- (3-ethoxy-4-methoxyphenyl) -3-phthalimidopropionamide is a 3- (3-ethoxy-4-methol which is a white solid (1.05 g, 94% yield). N-benzyloxy-3- (3-ethoxy-4-methoxyphenyl) -3-phthalimido-propanoic acid (869 mg, 2.36 mmol) to yield methoxyphenyl) -3-phthalimidopropionamide By the procedure of Example 1 from O-benzylhydroxylamine hydrochloride (444 mg, 2.78 mmol) of N, N'-carbonyldiimidazole (410 mg, 2.53 mmol) and tetrahydrofuran (6 mL). Prepared: mp, 165.0-166.0 ° C .; ¹ H NMR (CDCl ₃ ) δ 1.44 (t, J = 7.0 ㎐, 3H, C H ₃ ), 2.95 (dd, J = 5.8,14.0 ㎐, 1H, CH H ), 3.49 (t, J = 12.1 ㎐ , 1H, CH H ), 3.83 (s, 3H, C H ₃ ), 4.07 (q, J = 7.0 Hz, 2H, C H ₂ ), 4.77 (br s, 2H, PhC H ₂ ), 5.83 (dd, J = 6.0, 10.0 μs, 1H, NC H ), 6.79 (d, J = 8.0 μs, 1H, Ar), 7.06-7.09 (m, 2H, Ar), 7.25-7.85 (m, 5H, Ar), 7.66 -7.71 & 7.74-7.79 (2ms, 4H, Ar), 8.34 (br s, 1H, N H ); ¹³ C NMR (CDCl ₃ ) δ 14.68, 35.66, 51.54, 55.88, 64.34, 78.13, 111.32, 112.52, 120.08, 123.29, 128.52, 128.67, 129.06, 131.26, 131.76, 133.98, 134.98, 148.168, 149.38, 167.26. . Anal. Calcd for C ₂₇ H ₂₆ N ₂ O ₅ : C, 68.34; H, 5.52; N, 5.90. Found: C, 68.36; H, 5.47; N, 5.74.

Example  9

N- Benzyloxy -3- (3- Ethoxy -4- Methoxyphenyl ) -3- (3- Nitrophthalimido ) Propionamide

N-benzyloxy-3- (3-ethoxy-4-methoxyphenyl) -3- (3-nitrophthalimido) propionamide is N-benzyloxy which is a yellow solid (1.4 g, 86% yield) 3- (3-ethoxy-4-methoxyphenyl) -3- to yield 3- (3-ethoxy-4-methoxyphenyl) -3- (3-nitrophthalimido) propionamide O-benzylhydride of (3-nitrophthalimido) propanoic acid (1.30 mg, 3.14 mmol), N, N'-carbonyldiimidazole (533 mg, 3.28 mmol) and tetrahydrofuran (10 mL) Prepared by the procedure of Example 1 from loxylamine hydrochloride (550 mg, 3.45 mmol): mp, 137.0-139.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.30 (t, J = 6.8 Hz, 3H, C H ₃ ), 3.05-3.16 (m,, 2H, C H ₂ ), 3.72 (s, 3H, C H ₃ ), 4.09 (q, J = 6.8 ㎐, 2H, C H ₂ ), 4.64 (s, 2H, PhC H ₂ ), 5.68 (t, J = 7.8 ㎐, 1H, NC H ), 6,87-7.02 ( m, 3H, Ar), 7.23-7.41 (m, 5H, Ar), 8.11 (d, J = 8.1 kPa, 1H, Ar), 8.48 (s, 1H, Ar), 8.62 (dd, J = 1.8, 8.2 Iii, 1H, Ar), 11.24 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ14.64, 34.17, 50.76, 55.45, 63.71, 76.67, 111.68, 111.37, 112.37, 118.02, 119.76, 124.70, 128.16, 128.62, 129.75, 130.42, 132.56, 135.74, 147.73, 148.73 , 148.69, 151.50, 165.73, 165.99, 166.17. Anal. Calcd for C ₂₇ H ₂₅ N ₅ O ₈ : C, 62.42; H, 4. 85; N, 8.09. Found: C, 62.34; H, 4.71; N, 8.05.

Example  10

N- Benzyloxy -3- (3- Ethoxy -4- Methoxyphenyl ) -3- (1- Oxoisoindolinyl ) Propionamide

N-benzyloxy-3- (3-ethoxy-4-methoxyphenyl) -3- (1-oxoisoindolinyl) propionamide is N-benzyloxy- which is a white solid (1.73 g, 75% yield). 3- (3-ethoxy-4-methoxyphenyl) -3- (1 to yield 3- (3-ethoxy-4-methoxyphenyl) -3- (1-oxoisoindolinyl) propionamide O-benzylhydroxylamine hydro of oxoisoindolinyl) propanoic acid (1.78 g, 5.00 mmol), N, N'-carbonyldiimidazole (850 mg, 5.24 mmol) and tetrahydrofuran (10 mL) Prepared by the procedure of Example 1 from chloride (940 mg, 5.89 mmol): mp, 132.0-133.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ 1.29 (t, J = 6.9 Hz, 3H, C H ₃ ), 2.83 (d, J = 7.8 Hz, 2H, C H ₂ ), 3.72 (s, 3H, C H ₃ ), 3.93-4.02 (m, 2H, C H ₂ ), 4.09 (d, J = 17.5 ㎐, 1H, NCH H ), 4.51 (d, J = 17.5 ㎐, 1H, NCH H ), 4.59 (d , J = 11.3 kPa, 1H, PhCH H ), 4.66 (d, J = 11.2 kPa, 1H, PhCH H ), 5.74 (t, J = 7.8 kPa, 1H, NC H ), 6.83-6.93 (m, 3H, Ar), 7.21-7.29 & 7.45-7.59 (m, 8H, Ar), 7.68 (d, J = 7.4 ㎐, 1H, Ar), 11.17 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ14.66, 35.08, 46.18, 51.29, 55.43, 63.71, 76.69, 111.82, 112.11, 119.25, 122.82, 123.44, 127.85, 128.75, 131.31, 131.61, 132.17, 135.86, 141.68, 147.88, 147.88 , 148.45, 166.26, 166.88. Anal. Calcd for C ₂₇ H ₂₈ N ₂ O ₅ : C, 70.42; H, 6. 13; N, 6.08. Found: C, 70.31; H, 6.07; N, 5.88.

Example  11

3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxy -3- Phthalimidopropionamide

3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3-phthalimidopropionamide is a 3- (3-ethoxy-4-methol which is a white solid (800 mg, 77% yield) 3- (3-ethoxy-4-methoxyphenyl) -3-phthalimidopropionic acid (1.00 g, 2.71 mmol), N, N to yield methoxyphenyl) -N-hydroxy-3-phthalimidopropionamide Prepared by the procedure of Example 1 from hydroxylamine hydrochloride (208 mg, 2.99 mmol) of '-carbonyldiimidazole (461 mg, 2.84 mmol) and tetrahydrofuran (6 mL): mp, 163.0- 165.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.31 (t, J = 6.9 Hz, 3H, C H ₃ ), 3.11 (d, J = 7.9 Hz, 2H, C H ₂ ), 3.72 (s, 3H, C H ₃ ), 3.97 (q, J = 6.9 μs, 2H, C H ₂ ), 5.67 (t, J = 7.8 μs, 1H, NC H ), 6.90 (br s, 2H, Ar), 7.02 (br s, 1H, Ar), 7.86 (br s, 4H, Ar), 8.79 (br s, 1H, O H ), 10.59 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ 14.67, 34.22, 50.18, 55.44, 63.71, 111.73, 112.36, 119.65, 123.11, 131.18, 131.21, 134.56, 147.67, 148.53, 165.97, 167.61. Anal. Calcd for C ₂₀ H ₂₀ N ₂ O ₅ : C, 62.49; H, 5. 24; N, 7.29. Found: C, 62.43; H, 5.04; N, 7.20.

Example  12

N- Hydroxy -3- (3,4- Dimethoxyphenyl ) -3- Phthalimidopropionamide

N-hydroxy-3- (3,4-dimethoxyphenyl) -3-phthalimidopropionamide is N-hydroxy-3- (3,4-dimethoxy which is a white solid (1.52 g, 80% yield) 3- (3,4-dimethoxyphenyl) -3-phthalimidopropionic acid (1.82 g, 5.12 mmol), N, N'-carbonyldiimidazole (391 to yield phenyl) -3-phthalimidopropionamide mg, 5.63 mmol) and tetrahydrofuran (8 mL) were prepared by the procedure of Example 1 from hydroxylamine hydrochloride (391 mg, 5.63 mmol): mp, 163.0-165.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.31 (t, J = 6.9 μs, 3H, C H ₃ ), 3.11 (d, J = 7.9 μs, 2H, C H ₂ ), 3.72 (s, 3H, C H ₃ ), 3.97 (q, J = 6.9 μs, 2H, C H ₂ ), 5.67 (t, J = 7.8 μs, 1H, NC H ), 6.90 (br s, 2H, Ar), 7.02 (br s, 1H, Ar), 7.86 (br s, 4H, Ar), 8.79 (br s, 1H, O H ), 10.59 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ 14.67, 34.22, 50.18, 55.44, 63.71, 111.73, 112.36, 119.65, 123.11, 131.18, 131.21, 134.56, 147.67, 148.53, 165.97, 167.61. Anal. Calcd for C ₂₀ H ₂₀ N ₂ O ₅ : C, 62.49; H, 5. 24; N, 7.29. Found: C, 62.43; H, 5.04; N, 7.20.

Example  13

3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxy -3- (3- Nitrophthalimido ) Propionamide

3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (3-nitrophthalimido) propionamide is a 3- (3 which is a yellow solid (2.92 g, 77% yield) 3- (3-ethoxy-4-methoxyphenyl) -3- (to yield ethoxy-4-methoxyphenyl-N-hydroxy-3- (3-nitrophthalimido) propionamide 3-nitro-phthalimido) propanoic acid (3.64 g, 8.86 mmol), N, N'-carbonyldiimidazole (1.50 g 9.25 mmol) and tetrahydrofuran (20 mL) hydroxylamine hydrochloride ( 672 mg, 9.67 mmol) was prepared by the procedure of Example 1: mp, 162.5-163.5 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.31 (t, J = 6.9 Hz, 3H, C H ₃ ) , 3.02 (dd, J = 7.5, 14.8 μs, 1H, CH H ), 3.17 (dd, J = 8.3, 14.8 μs, 1H, CH H ), 3.72 (s, 3H, C H ₃ ), 4.00 (q, J = 6.9 μs, 2H, C H ₂ ), 5.68 (t, J = 7.7 μs, 1H, NC H ), 6.87-6.96 (m, 2H, Ar), 7.01 (br s, 1H, Ar), 8.05 ( t, J = 7.7 ㎐, 1H, Ar), 8.15 (d, J = 7.0 ㎐, 1H, Ar), 8.27 (d, J = 7.8 ㎐, 1H, Ar), 8.82 (s, 1H, O H ), 10.62 (br s, 1H, NH); ¹³ C NMR (DMSO-d ₆ ) δ14.66, 33.92, 50.59, 55.46, 63.74, 111.69, 112.59, 119.89, 122.48, 126.91, 128.43, 130.42, 133.13, 136.35, 144.33, 147.67, 162.99, 165.70, 165,87.Anal.Calcd for C ₂₀ H ₁₉ N ₃ O ₈ + 0.4 mole ethyl acetate: C, 55.83; H, 4.86; N, 8.96. Found: C, 55.86; H, 4.94; N, 8.73.

Example  14

N- Hydroxy -3- {3- (2- Propoxy )-4- Methoxyphenyl } -3- Phthalimidopropionamide

N-hydroxy-3- {3- (2-propoxy) -4-methoxyphenyl} -3-phthalimidopropionamide is N-hydroxy-3- which is a white solid (1.42 g, 68% yield) 3- {3- (2-propoxy) -4-methoxyphenyl} -3-phthalimido to yield {3- (2-propoxy) -4-methoxyphenyl} -3-phthalimidopropionamide Procedure of Example 1 from hydroxylamine hydrochloride (481 mg, 6.92 mmol) of propanoic acid (2.0 g, 5.2 mmol), carbonyldiimidazole (1.02 g, 6.29 mmol) and tetrahydrofuran (10 mL) Prepared by: mp, 119.0-121.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ 1.24 (d, J = 6.0 Hz, C H ₃ ), 1.243 (d, J = 6.0 Hz, 3H, C H ₃ ), 3.12 (d, J = 7.9 Hz, 2H, C H ₂ ), 3.71 (s, 3H, C H ₃ ), 4.45-4.51 (m, 1H, C H ), 5.68 (t, J = 7.9 ㎐, 1H, NC H ), 6.91 (br s, 2H, Ar), 7.05 (br s, 1H, Ar), 7.84-7.86 (m, 4H, Ar), 8.79 (br s, 1H, O H ), 10.60 (1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ21.80, 21.88, 34.19, 50.13, 55.49, 70.44, 112.18, 114.97, 120.12, 123.11, 131.13, 131.21, 134.59, 146.37, 149.51, 165.99, 167.62; Anal. Calcd for C ₂₁ H ₂₂ N ₂ O ₆ 0.9 H ₂ 0: C, 60.83; H, 5.79; N, 6.76. Found: C, 60.83; H, 5.73; N, 6.56; H ₂ 0, 4.02.

Example  15

3- (3- Ethoxy -4- Methoxyphenyl ) -3- (3,6- Difluorophthalimido ) -N- Hydroxy - Propionamide

3- (3-ethoxy-4-methoxyphenyl) -3- (3,6-difluorophthalimido) -N-hydroxy-propionamide is a white solid (340 mg, 57% yield) 3- (3-ethoxy-4 to yield 3- (3-ethoxy-4-methoxyphenyl) -3- (3,6-difluorophthalimido) -N-hydroxy-propionamide Of -methoxyphenyl) -3- (3,6-difluorophthalimidopropanoic acid (580 mg, 1.43 mmol), carbonyldiimidazole (255 mg, 1.57 mmol) and tetrahydrofuran (8 mL) Prepared by the procedure of Example 1 from hydroxylamine hydrochloride (120 mg, 1.73 mmol): mp, 171.0-172.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.32 (t, J = 6.9 Hz, 3H, C H ₃ ), 3.03 (dd, J = 7.9, 14.8 kPa, 1H, CH H ), 3.16 (dd, J = 8.1, 14.9 kPa, 1H, CH H ), 3.71 (s, 3H, C H ₃ ), 3.91 (q, J = 6.9 μs, 2H, C H ₂ ), 5.62 (t, J = 7.8 μs, 1H, NC H ), 6.878-6.95 (m, 2H, Ar), 6.99 (br s, 1H , Ar), 7.74 (t, J _{H -F} = 5.8 kPa, 2H, Ar), 8.81 (br s, 1H, O H ), 10.61 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ 14.64 , 33.88, 50.29, 55.44, 63.71, 111.64, 112.44, 118.02 (t, J _{C -F} = 9.2 μs), 119.77, 125.47 (t, J _CF = 15 μs), 130.42, 147.65, 148.59, 152.93 (dd, J _{C -F} = 4.2, 261 iii), 163.49, 165.84; Anal.Calcd for C ₂₀ H ₁₈ N ₂ O ₆ F ₂ : C, 57.14; H, 4.32; N, 6.66.Found: C, 56.93; H, 4.37 N, 6.31.

Example  16

3- (4- Aminophthalimido ) -3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxypropionamide

3- (4-Aminophthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide was added to N in ethyl acetate / methol / tetrahydrofuran (150 mL each). -Benzyloxy-3- (3-ethoxy-4-methoxyphenyl) -3- (4-nitrophthalimido) -propionamide (2.3 g, 4.42 mmol) with Pd (OH) ₂ / C (600 mg) mixture was shaken under hydrogen. After 24 hours, the suspension was filtered through a Celite pad and then washed with methanol (30 mL) and methylene chloride (30 mL). The filtrate was concentrated to yield oil in vacuum. Oil to yield 3- (4-aminophthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide as a yellow solid (1.8 g, 100% yield) (oil) was stirred with ethyl acetate (10 mL): mp, 193.0-195.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.31 (t, J = 6.9 Hz, 3H, C H ₃ ), 3.05 (d, J = 7.9 Hz, 2H, C H ₂ ), 3.71 (s, 3H, C H ₃ ), 3.96 (q, J = 7.0 μs, 2H, C H ₂ ), 5.57 (t, J = 7.9 μs, 1H, NC H ), 6.47 (br s, 2H, N H ₂ ), 6.77 (dd , J = 2.0, 8.3 μs, 1H, Ar), 6.83-6.88 (m, 3H, Ar), 6.99 (br s, 1H, Ar), 7.45 (d, J = 8.3 μs, 1H, Ar), 8.78 ( br s, 1 H, 0 H ), 10.55 (1 H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ 14.69, 34.51, 49.75, 55.45, 63.73, 106.82, 111.74, 112.38, 116.32, 116.73, 119.60, 124.89, 131.85, 134.18, 147.62, 148.42, 155.00, 166.111, 167.70, 168.00 ; Anal. Calcd for C ₂₀ H ₂₁ N ₃ O ₅ : C, 60.14; H, 5. 30; N, 10.52. Found: C, 60.00; H, 5. 34; N, 10.30.

Example  17

N- Hydroxy -3- (3,4- Dimethoxyphenyl ) -3- (1- Oxoisoindolinyl ) Propionamide

N-hydroxy-3- (3,4-dimethoxyphenyl) -3- (1-oxoisoindolinyl) propionamide is a white solid (4.1 g, 79% yield) N-hydroxy-3- ( 3,4-dimethoxyphenyl) -3- (1-oxoisoindolinyl) propionamide yields 3- (3,4-dimethoxyphenyl) -3- (1-oxoisoindolinyl) propanoic acid to yield Prepared by the procedure of Example 1 from hydroxylamine hydrochloride (1.30 g, 19.1 mmol) of (5.00 g, 14.7 mmol), carbonyldiimidazole (2.49 g, 15.4 mmol) and tetrahydrofuran (15 mL). Mp: 188.5-189.5 ° C .; ¹ H NMR (DMSO-d ₆ ) δ2.82-2.87 (m, 2H, C H ₂ ), 3.71 (s, 3H, C H ₃ ), 3.74 (s, 3H, C H ₃ ), 4.15 (d, J = 17.5 ㎐, 1H, NCH H ), 4.63 (d, J = 17.5 ㎐, 1H, NCH H ), 5.74 (t, J = 7.7 ㎐, 1H, NC H ), 6.85-6.93 (m, 3H, Ar ), 7.45-7.69 (m, 4H, Ar), 8.83 (br s, 1H, O H ), 10.60 (1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ35.11, 46.26, 51.25, 55.50, 111.09, 111.76, 119.19, 122.79, 123.43, 127.84, 131.29, 132.27, 141.68, 148.27, 148.69, 166.03, 166.84; Anal. Calcd for C ₁₉ H ₂₀ N ₂ O ₅ : C, 64.04; H, 5. 66; N, 7.86. Found: C, 64.08; H, 5.55; N, 7.86.

Example  18

3- (3- Cyclopentyloxy -4- Methoxyphenyl ) -N- Hydroxy -3- (1- Oxoisoindolinyl ) Propionamide

3- (3-cyclopentyloxy-4-methoxyphenyl) -N-hydroxy-3- (1-oxoisoindolinyl) propionamide is a 3- (3 that is a white solid (950 mg, 91% yield) 3- (3-cyclopentyloxy-4-methoxyphenyl) -3 to yield -cyclopentyloxy-4-methoxyphenyl) -N-hydroxy-3- (1-oxoisoindolinyl) propionamide Hydroxylamine hydrochloride (230 mg, in-(1-oxoisoindolinyl) propanoic acid (1.00 g, 2.53 mmol), carbonyldiimidazole (430 mg, 2.66 mmol) and tetrahydrofuran (5 mL) 3.29 mmol) was prepared by the procedure of Example 1: mp, 183.0-184.5 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.54-1.82 (m, 8H, C ₅ H ₈ ), 2.82-2.86 (m, 2H, C H ₂ ), 3.70 (s, 3H, C H ₃ ), 4.13 (d, J = 17.5 ㎐, NCH H ), 4.55 (d, J = 17.5 ㎐, 1H, NCH H ), 4.73 (m, 1H, C H ), 5.74 (t, J = 7.6 ㎐, 1H, NC H ), 6.85-6.93 (m, 3H, Ar), 7.47-7.70 (m, 4H, Ar), 8.84 (br s, 1H, O H ), 10.60 (1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ23.50, 32.11, 32.18, 46.20, 51.17, 79.52, 112.21, 114.00, 119.14, 122.78, 123.43, 127.85, 131.31, 131.86, 132.27, 141.65, 146.87, 149.07, 166.04 ; Anal. Calcd for C ₂₃ H ₂₆ N ₂ O ₅ 0.7 H ₂ 0: C, 65.30; H, 6.53; N, 6.62. Found: C, 65.59; H, 6. 38; N, 6.65; H ₂ 0, 2.94.

Example  19

 N- Benzyloxy -3- (3- Ethoxy -4- Methoxyphenyl ) -3- (4- Nitrophthalimido ) Propionamide

N-benzyloxy-3- (3-ethoxy-4-methoxyphenyl) -3- (4-nitrophthalimido) propionamide is N-benzyloxy which is a yellow solid (2.1 g, 59% yield) 3- (3-ethoxy-4-methoxyphenyl) -3- to yield 3- (3-ethoxy-4-methoxyphenyl) -3- (4-nitrophthalimido) propionamide O-benzylhydroxylamine hydrochloride of (4-nitrophthalimido) propanoic acid (2.84 g, 6.85 mmol), carbonyldiimidazole (1.22 g, 7.52 mmol) and tetrahydrofuran (15 mL) 1.32 g, 8.27 mmol) was prepared by the procedure of Example 1: mp, 159.0-161.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.30 (t, J = 6.9 Hz, 3H, C H ₃ ), 3.03 (dd, J = 7.7, 14.8 Hz, 1H, CH H ), 3.15 (dd, J = 8.0, 14.9 ㎐, 1H, CH H ), 3.72 (s, 3H, C H ₃ ), 3.96 (q, J = 6.9 ㎐, 2H, C H ₂ ), 4.64 (s, 2H, PhC H ₂ ), 5.66 (t, J = 7.8 μs, 1H, NC H ), 6.87-6.95 (m, 2H, Ar), 6.99 (br s, 1H, Ar), 7.23-7.41 (m, 5H, Ar), 8.06 (t, J = 7.7 μs, 1H, Ar), 8.14-8.18 (m, 1H, Ar), 8.26-8.31 (m, 1H, Ar), 11.24 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ 14.66, 34.09, 50.62, 55.46, 63.82, 76.69, 111.86, 112.46, 119.83, 122.47, 126.94, 128.18, 128.67, 130.28, 133.08, 135.79, 136.38, 144.36, 147.68, 148.68 , 162.99, 165.69, 166.18. Anal. Calcd for C ₂₇ H ₂₅ N ₃ O ₈ : C, 62.42; H, 4. 85; N, 8.09. Found: C, 62.12; H, 4.92; N, 7.82.

Example  20

3- (3- Aminophthalimido ) -3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxypropionamide

N-benzyloxy-3- (3-ethoxy-4-methoxyphenyl) -3- (4-nitrophthalimido) -propionamide (2.3 g, 4.42 mmol) and ethyl acetate / metall (150 each) mL) was shaken under 50-60 psi of hydrogen gas (H ₂ ) at 10% Pd / C (230 mg). After 3 days, the suspension was filtered through a Celite pad and then washed with methanol (75 mL) and methylene chloride (75 mL). The filtrate was concentrated to yield oil in vacuum. Oil to yield 3- (3-aminophthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide as a yellow solid (650 mg, 64% yield) (oil) was stirred with ether (20 mL): mp, 143.0-145.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ 1.39 (t, J = 6.9 μs, 3H, C H ₃ ), 3.16 (d, J = 7.8 μs, 2H, C H ₂ ), 3.79 (s, 3H, C H ₃ ), 4.05 (q, J = 6.9 ㎐, 2H, C H ₂ ), 5.68 (t, J = 7.8 ㎐, 1H, NC H ), 6.55 (br s, 2H, N H ₂ ), 6.98-7.08 (m, 5H, Ar), 7.47-7.53 (m, 1H, Ar), 8.88 (br s, 1H, O H ), 10.66 (1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ 14.70, 34.37, 49.65, 55.47, 63.75, 110.68, 111.77, 112.39, 119.61, 121.40, 131.69, 132.03, 135.19, 146.48, 147.65, 148.47, 166.14, 167.81, 169.18; Anal. Calcd for C ₂₀ H ₂₁ N ₃ O ₆ C, 60.14; H, 5. 30; N, 10.52. Found: C, 59.76; H, 5. 21; N, 10.30.

Example  21

N- Hydroxy -N- methyl -3- (3- Ethoxy -4- Methoxyphenyl ) -3- (1- Oxoisoindolinyl ) Propionamide

N-hydroxy-N-methyl-3- (3-ethoxy-4-methoxyphenyl) -3- (1-oxoisoindolinyl) propionamide is N as a white solid (650 mg, 61% yield) 3- (3-ethoxy-4-meth) to yield -hydroxy-N-methyl-3- (3-ethoxy-4-methoxyphenyl) -3- (1-oxoisoindolinyl) propionamide N-methyl- of methoxyphenyl) -3- (1-oxoisoindolinyl) propanoic acid (1.00 g, 2.8 mmol), carbonyldiimidazole (500 mg, 3.1 mmol) and tetrahydrofuran (10 mL) Prepared by the procedure of Example 1 from hydroxylamine hydrochloride (300 mg, 3.5 mmol): mp, 122.0-124.5 ° C .; ¹ H NMR (CDCl ₃ ) δ1.43 (t, J = 7.0 Hz, 3H, C H ₃ ), 3.14 (s, 3H, NC H ₃ ), 3.37-3.48 (m, 2H, C H ₂ ), 3.86 (s, 3H, C H ₃ ), 4.02 (q, J = 7.0 ㎐, 2H, C H ₂ ), 4.11 (d, J = 17.2 ㎐, NCH H ), 4.51 (d, J = 17.2 ㎐, 1H, NCH H ), 5.95 (dd, J = 6.5, 10.9 μs, 1H, NC H ), 6.83-6.97 (m, 3H, Ar), 7.34-7.55 (m, 3H, Ar), 7.81 (d, J = 7.1 ㎐, 1 H, Ar), 9.44 (br s, 1 H, O H ); ¹³ C NMR (DMSO-d ₆ ) δ14.71, 36.04, 38.11, 48.14, 52.36, 55.95, 64.52, 111.42, 112.42, 119.45, 122.95, 123.63, 128.06, 130.57, 131.88, 141.72, 148.65, 149.18, 170.00, 170.17 ; Anal. Calcd for C ₂₁ H ₂₄ N ₂ O ₅ : C, 65.61; H, 6. 29; N, 7.29. Found: C, 65.56; H, 6. 26; N, 7.09.

Example  22

N- Hydroxy -3- (3- (1- methyl ) Ethoxy -4- Methoxyphenyl ) -3- (1- Oxoisoindolinyl ) Propionamide

N-hydroxy-3- (3- (1-methyl) ethoxy-4-methoxyphenyl) -3- (1-oxoisoindolinyl) propionamide is a white solid (4.1 g, 79% yield) 3- (3- (1-methyl) to yield N-hydroxy-3- (3- (1-methyl) ethoxy-4-methoxyphenyl) -3- (1-oxoisoindolinyl) propionamide ) Ethoxy-4-methoxyphenyl) -3- (1-oxoisoindolinyl) propanoic acid (500 mg, 1.35 mmol), carbonyldiimidazole (230 mg, 1.42 mmol) and tetrahydrofuran (5 mL) was prepared by the procedure of Example 1 from hydroxylamine hydrochloride (120 mg, 1.75 mmol): mp, 173.0-174.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ 1.19 (d, J = 8.2 μs, 3H, C H ₃ ), 1.23 (d, J = 8.2 μs, 3H, C H ₃ ), 2.82-2.85 (m, 2H , C H ₂ ), 3.71 (s, 3H, C H ₃ ), 4.11 (d, J = 17.5 μs, NCH H ), 4.46-4.58 (m, 2H, C H, NCH H ), 5.73 (t, J = 7.5 μs, 1H, NC H ), 6.86-6.93 (m, 3H, Ar), 7.47-7.69 (m, 4H, Ar), 8.83 (br s, 1H, O H ), 10.60 (1H, N H ) ; ¹³ C NMR (DMSO-d ₆ ) δ21.99, 22.09, 35.17, 46.41, 51.35, 55.67, 70.61, 112.48, 115.08, 119.79, 122.97, 123.62, 178.05, 131.51, 132.04, 132.45, 141.83, 146.71, 149.63, 166.23 , 167.07; Anal. Calcd for C ₂₁ H ₂₄ N ₂ O ₅ : C, 65.61; H, 6. 29; N, 7.29. Found: C, 60.58; H, 6. 18; N, 6.47.

Example  23

3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxy -(3- Hydroxyphthalimido ) Propionamide

3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy- (3-hydroxyphthalimido) propionamide is a yellow solid (580 mg, 80% yield) 3- (3-ethoxy-4-methoxyphenyl)-(3-hydroxyphthal) to yield methoxy-4-methoxyphenyl) -N-hydroxy- (3-hydroxyphthalimido) propionamide Imido) Examples from hydroxylamine hydrochloride (380 mg, 5.47 mmol) of propanoic acid (500 mg, 1.35 mmol), carbonyldiimidazole (0.70 g, 1.8 mmol) and tetrahydrofuran (10 mL) Prepared by the procedure of 1: mp, 209.0-210.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.31 (t, J = 6.9 ㎐, 3H, C H ₃ ), 3.08 (d, J = 7.9 ㎐, 2H, C H ₂ ), 3.71 (s, 3H, C H ₃ ), 3.97 (q, J = 6.9 μs, 2H, C H ₂ ), 5.62 (t, J = 7.9 μs, 1H, NC H ), 6.88 (br s, 2H, Ar), 6.99 (br s, 1H, Ar), 7.18 (d, J = 8.3 kPa, 1H, Ar), 7.22 (d, J = 7.1 kPa, 1H, Ar), 7.58 (dd, J = 7.4, 8.2 kPa, 1H, Ar), 8.88 (br s, 1 H, 0 H ), 10.58 (br s, 1 H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ24.73, 44.31, 59.77, 65.49, 73.77, 121.76, 122.40, 123.84, 124.29, 129.66, 133.41, 141.53, 143.24, 146.04, 157.66, 158.49, 165.49, 176.14, 176.14. ; Anal. Calcd for C ₂₀ H ₂₀ N ₂ O ₇ : C, 60.00; H, 5.03; N, 7.00. Found: C, 59.99; H, 5.08; N, 7.03.

Example  24

3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxy -3- (4- Hydroxyphthalimido ) Propionamide

3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (4-hydroxyphthalimido) propionamide is a 3- (3 that is a yellow solid (1.8 g, 44% yield). 3- (3-ethoxy-4-methoxyphenyl) -3- to yield -ethoxy-4-methoxyphenyl) -N-hydroxy-3- (4-hydroxyphthalimido) propionamide Hydroxyamine hydrochloride (1.13 g, of (4-hydroxyphthalimido) propanoic acid (4.0 g, 10.4 mmol), carbonyldiimidazole (2.02 g, 12.46 mmol) and tetrahydrofuran (20 mL) 16.3 mmol) was prepared by the procedure of Example 1: mp, 143.5-146.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.31 (t, J = 6.9 μs, 3H, C H ₃ ), 3.09 (d, J = 7.9 μs, 2H, C H ₂ ), 3.72 (s, 3H, C H ₃ ), 3.98 (q, J = 6.9 μs, 2H, C H ₂ ), 5.62 (t, J = 7.9 μs, 1H, NC H ), 6.89 (br s, 2H, Ar), 7.01 (br s, 1H, Ar), 7.09-7.12 (m, 2H, Ar), 7.66-7.69 (m, 1H, Ar), 8.88 (br s, 1H, O H ), 10.59 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ24.71, 44.39, 60.08, 65.47, 73.75, 119.72, 121.76, 122.36, 129.66, 130.53, 131.37, 135.52, 141.49, 144.08, 157.68, 158.51, 173.43, 176.09, 177.49; Anal. Calcd for C ₂₀ H ₂₀ N ₂ O ₇ + 0.35 H ₂ 0: C, 59.07; H, 5.13; N, 6.89. Found: C, 58.84; H, 5.05; N, 7.26.

Example  25

3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxy -3- (3- Methylphthalimido ) Propionamide

3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (3-methylphthalimido) propionamide is a white solid (1.4 g, 90% yield) 3- (3-ethoxy-4-methoxyphenyl) -3- (to yield ethoxy-4-methoxyphenyl) -N-hydroxy-3- (3-methylphthal-imido) propionamide 3-methylphthalimido) propanoic acid (1.50 g, 3.91 mmol), carbonyldiimidazole (2.02 g, 12.46 mmol) and tetrahydrofuran (5 mL) of hydroxylamine hydrochloride (330 mg, 4.75 mmol) Was prepared by the procedure of Example 1: mp, 165.0-166.5 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.32 (t, J = 6.9 ㎐, 3H, C H ₃ ), 2.61 (s, 3H, C H ₃ ), 3.10 (d, J = 7.9 ㎐, 2H, C H ₂ ), 3.72 (s, 3H, C H ₃ ), 3.98 (q, J = 7.0 μs, 2H, C H ₂ ), 5.66 (t, J = 7.8 μs, 1H, NC H ), 6.87-6.90 ( m, 2H, Ar), 7.02 (br s, 1H, Ar), 7.57-7.69 (m, 3H, Ar), 8.80 (br s, 1H, O H ), 10.59 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ14.71, 16.99, 34.21, 49.95, 55.45, 63.73, 111.72, 112.38, 119.70, 120.76, 127.79, 131.67, 134.06, 136.66, 137.29, 147.65, 148.168, 166.06, 167.55. ; Anal. Calcd for C ₂₁ H ₂₂ N ₂ O ₆ + H ₂ 0: C, 60.57; H, 5.81; N, 6.73. Found: C, 60.83; H, 5.72; N, 6.53.

Example  26

3- (3- Acetoamidophthalimido ) -3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxypropionamide

3- (3-acetoamidophthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropion-amide is 3- as a white solid (1.0 g, 48% yield). 3- (3-acetoamidophthalimido) -3 to yield (3-acetoamidophthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide Hydroxylamine hydrochloride of-(3-ethoxy-4-methoxyphenyl) propanoic acid (2.0 g, 4.7 mmol), carbonyldiimidazole (1.14 g, 7.03 mmol) and tetrahydrofuran (10 mL) (651 mg, 9.37 mmol) was prepared by the procedure of Example 1: mp, 117.0-119.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.31 (t, J = 6.9 μs, 3H, C H ₃ ), 2.19 (s, 3H, C H ₃ ), 3.09 (d, J = 7.9 μs, 2H, C H ₂ ), 3.72 (s, 3H, C H ₃ ), 3.98 (q, J = 7.0 Hz, 2H, C H ₂ ), 5.65 (t, J = 7.8 Hz, 1H, NC H ), 6.87-6.95 ( m, 2H, Ar), 6.99 (br s, 1H, Ar), 7.54 (d, J = 7.9 kPa, 1H, Ar), 7.77 (t, J = 7.45 kPa, 1H, Ar), 8.41-8.47 (m , 1H, Ar), 8.80 (br s, 1H, 0 H ), 10.59 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ24.69, 34.20, 44.09, 60.04, 65.48, 73.79, 121.78, 122.43, 126.69, 127.97, 129.64, 135.83, 141.44, 145.75, 146.38, 157.70, 158.59, 175.97, 177.13. , 179.22; Anal. Calcd for C ₂₂ H ₂₃ N ₃ O ₇ + 03 H ₂ 0: C, 59.14; H, 5. 32; N, 9.40. Found: C, 59.32; H, 5. 33; N, 9.02.

Example  27

3- (4- Acetoamidophthalimido ) -3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxypropionamide

3- (4-acetoamidophthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropion-amide is 3- as a yellow solid (0.9 g, 43% yield) 3- (4-acetoamidophthalimido) -3 to yield (4-acetoamido phthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide Hydroxylamine hydrochloride of-(3-ethoxy-4-methoxyphenyl) propanoic acid (2.0 g, 4.7 mmol), carbonyldiimidazole (836 mg, 5.16 mmol) and tetrahydrofuran (8 mL) (391 mg, 5.63 mmol) was prepared by the procedure of Example 1: mp, 138.0-140.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.31 (t, J = 6.9 ㎐, 3H, C H ₃ ), 2.12 (s, 3H, C H ₃ ), 3.09 (d, J = 7.9 ㎐, 2H, C H ₂ ), 3.72 (s, 3H, C H ₃ ), 3.98 (q, J = 6.9 ㎐, 2H, C H ₂ ), 5.64 (t, J = 7.8 ㎐, 1H, NC H ), 6.89 (br s , 2H, Ar), 7.01 (br s, 1H, Ar), 7.77-7.86 (m, 2H, Ar), 8.17 (br s, 1H, Ar), 8.80 (br s, 1H, O H ), 10.58 ( br s, 2H, 2N H ); ¹³ C NMR (DMSO-d ₆ ) δ 14.69, 24.18, 34.27, 50.15, 55.43, 63.69, 111.68, 122.26, 122.46, 119.63, 123.11, 124.37, 124.79, 131.26, 132.76, 114.87, 147.65, 148.48, 165.98, 167.98 , 169.22; Anal. Calcd for C ₂₂ H ₂₃ N ₃ O ₇ + 03 H ₂ 0: C, 59.86; H, 5. 25; N, 9.52. Found: C, 59.49; H, 5. 24; N, 9.40.

Example  28

3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxy -3- (1,3- Dioxo -2,3- Dehydro -1H- Benzo [e] isoindole -2 days) Propionamide

3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (1,3-dioxo-2,3-dihydro-1H-benzo [ e ] isoindol-2'-yl Propionamide is a 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (1,3-dioxo-2,3- which is a yellow solid (1.14 g, 74% yield) 3- (3-ethoxy-4-methoxyphenyl) -3- (1,3-dioxo-2, to yield dihydro-1H-benzo [ e ] isoindol-2'-yl) propionamide 3-dihydro-1H-benzo [ e ] isoindol-2'-yl) propanoic acid (1.50 g, 3.57 mmol), carbonyldiimidazole (609 mg, 3.76 mmol) and tetrahydrofuran (8 mL) Was prepared by the procedure of Example 1 from hydroxylamine hydrochloride (287 mg, 4.13 mmol): mp, 160.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.31 (t, J = 6.9 Hz, 3H, C H ₃ ), 3.15 (d, J = 7.8 Hz, 2H, C H ₂ ), 3.72 (s, 3H, C H ₃ ), 3.99 (q, J = 7.0 μs, 2H, C H ₂ ), 5.72 (t, J = 7.7 μs, 1H, NC H ), 6.88-7.07 (m, 3H, Ar), 7.71-7.88 ( m, 3H, Ar), 8.15 (d, J = 8.0 kPa, 1H, Ar), 8.37 (d, J = 8.2 kPa, 1H, Ar), 8.78 (m, 2H, O H , Ar), 10.62 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ 14.70, 34.40, 50.12, 55.44, 63.72, 111.72, 112.36, 118.39, 119.68, 122.79, 126.22, 127.09, 128.84, 129.16, 129.88, 130.75, 131.30, 135.48, 136.18, 147.18 , 148.51, 168.09, 168.13, 168.89; Anal. Calcd for C ₂₄ H ₂₂ N ₂ O ₆ + 0.4 H ₂ 0: C, 65.27; H, 5.20; N, 6.34. Found: C, 65.30; H, 5. 17; N, 6.46.

Example  29

3- (4- Tert - Butylphthalimido ) -3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxypropionamide

3- (4-tert-butylphthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide is a 3- ( 3- (4-tert-butylphthalimido) -3- to yield 4-tert-butylphthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide Hydroxylamine hydrochloride of (3-ethoxy-4-methoxyphenyl) propanoic acid (2.0 g, 4.7 mmol), carbonyldiimidazole (800 mg, 4.93 mmol) and tetrahydrofuran (10 mL) 377 mg, 5.43 mmol) was prepared by the procedure of Example 1: mp, 127.5-129.5 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.24-1.44 (m, 12H, 4C H ₃ ), 3.09 (d, J = 7.9 ㎐, 2H, C H ₂ ), 3.71 (s, 3H, C H ₃ ) , 3.97 (q, J = 6.9 μs, 2H, C H ₂ ), 5.66 (t, J = 7.8 μs, 1H, NC H ), 6.89 (br s, 2H, Ar), 7.01 (br s, 1H, Ar ), 7.76-7.87 (m, 3H, Ar), 8.79 (br s, 1H, O H ), 10.59 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ14.73, 30.76, 34.29, 35.48, 50.14, 55.46, 63.72, 111.69, 112.27, 119.59, 119.98, 123.07, 128.75, 131.28, 131.45, 131.55, 147.69, 148.49, 158.32. , 167.53, 167.85; Anal. Calcd for C ₂₄ H ₂₈ N ₂ O ₆ : C, 65.44; H, 6. 41; N, 6.36. Found: C, 64.34; H, 6. 29; N, 7.04.

Example  30

3- (3,4- Dimethoxyphenyl ) -N- Hydroxy -3- (1,3- Dioxo -2,3- Dehydro -1H- Benzo [e] isoindole -2 days) Propionamide

3- (3,4-dimethoxyphenyl) -N-hydroxy-3- (1,3-dioxo-2,3-dihydro-1H-benzo [ e ] isoindol-2'-yl) propionamide Is a yellow solid (150 mg, 15% yield) 3- (3,4-dimethoxyphenyl) -N-hydroxy-3- (1,3-dioxo-2,3-dihydro-1H-benzo [ e ] 3- (3,4-dimethoxyphenyl) -3- (1,3-dioxo-2,3-dihydro-1H-benzo [to yield isoindole-2'-yl) propionamide e ] hydroxylamine hydrochloride (180) of isoindol-2'-yl) propanoic acid (0.90 g, 2.2 mmol), carbonyldiimidazole (382 mg, 2.36 mmol) and tetrahydrofuran (10 mL) mg, 2.59 mmol) was prepared by the procedure of Example 1: mp, 218.0-220.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ3.17 (d, J = 7.8 Hz, 2H, C H ₂ ), 3.72 (s, 3H, C H ₃ ), 3.75 (s, 3H, C H ₃ ), 5.74 (t, J = 7.8 μs, 1H, NC H ), 6.88-7.01 (m, 2H, Ar), 7.08 (br s, 1H, Ar), 7.75-7.89 (m, 3H, Ar), 8.17 (d, J = 8.0 μs, 1H, Ar), 8.40 (d, J = 8.2 μs, 1H, Ar), 8.78-8.81 (m, 2H, O H , Ar), 10.62 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ34.42, 50.11, 55.48, 111.29, 111.66, 118.35, 119.59, 123.77, 126.21, 127.08, 128.80, 129.13, 129.84, 130.73, 131.38, 135.44, 136.168, 148.06, 148.06. , 168.09, 168.86; Anal. Calcd for C ₂₃ H ₂₀ N ₂ O ₆ : C, 65.71; H, 4.79; N, 6.66. Found: C, 65.06; H, 4. 62; N, 6.44.

Example  31

3- (3,4- Dimethoxyphthalimido ) -3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxypropionamide

3- (3,4-dimethoxyphthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropion-amide is a white solid (130 mg, 15% yield) 3- (3,4-dimethoxyprop to yield 3- (3,4-dimethoxyphthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide Delimido) -3- (3-ethoxy-4-methoxyphenyl) propanoic acid (0.83 g, 1.9 mmol), carbonyldiimidazole (501 mg, 3.09 mmol) and tetrahydrofuran (10 mL) Was prepared by the procedure of Example 1 from hydroxylamine hydrochloride (391 mg, 5.63 mmol): mp, 158.0 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.31 (t, J = 7.0 Hz, 3H, C H ₃ ), 3.08 (d, J = 7.8 Hz, 2H, C H ₂ ), 3.72 (s, 3H, C H ₃ ), 3.92 (q, J = 7.0 μs, 2H, C H ₂ ), 5.62 (t, J = 7.9 μs, 1H, NC H ), 6.89 (br s, 2H, Ar), 7.00 (br s, 1H, Ar), 7.35-7.38 (m, 1H, Ar), 7.54 (d, J = 8.0 kPa, 1H, Ar), 8.78 (br s, 1H, O H ), 10.56 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ14.65, 34.25, 50.03, 55.44, 56.61, 61.73, 63.71, 105.66, 111.74, 112.41, 117.11, 119.52, 119.68, 121.53, 123.48, 131.33, 147.61, 148.49, 157.65, 165.165, , 163.00, 166.82; Anal. Calcd for C ₂₂ H ₂₄ N ₂ O ₈ : C, 59.45; H, 5. 44; N, 6.30. Found: C, 58.01; H, 5. 32; N, 6.02.

Example  32

Tablets each containing 50 mg of N-hydroxy-3- (3,4-dimethoxyphenyl) -3- (1-oxoisoindolinyl) propionamide could be prepared by the following method:

Component (for 1000 tablets)

N-hydroxy-3- (3,4-dimethoxyphenyl)-

3- (1-oxoisoindolinyl)

Propionamide ......................................... 50.0 g

Lactose ......... 50.7g

Wheat starch ... 7.5g

Polyethylene Glycol 6000 ......... 5.0g

Talc ..... 5.0g

Magnesium stearate ..... 1.8g

Demineralized water ... q.s.

Solid materials were first passed through a sieve having a grid width of 0.6 mm. The active ingredient, lactose, talc, magnesium stearate and half starch were then mixed. The other half of starch was suspended in 40 mL of water and the suspension was added to a boiling polyethylene glycol solution in 100 mL of water. The resulting paste was added to the fine powdered material and, if necessary, water was added to make the mixture grainy. The grains were dried overnight at 35 ° C., passed through a sieve with a 1.2 mm grid width and compressed to make tablets approximately 6 mm in diameter with both sides concave.

Example  33

Tablets each containing 100 mg of N-hydroxy-3- (3,4-dimethoxyphenyl) -3-phthalimidopropionamide could be prepared by the following method:

Component (for 1000 tablets)

N-hydroxy-3- (3,4-dimethoxyphenyl)-

3-phthalimido-

Propionamide ......................................... 100.0 g

Lactose ... 100.0 g

Wheat starch ... 47.0 g

Magnesium stearate ...... 3.0 g

All solid materials were first passed through a sieve having a grid width of 0.6 mm. The active ingredient, lactose, magnesium stearate and half starch were then mixed. The other half of starch was suspended in 40 mL of water and the suspension was added to 100 mL of water. The resulting paste was added to the fine powdered material and, if necessary, water was added to make the mixture grainy. The grains were dried overnight at 35 ° C., passed through a sieve with a 1.2 mm grid width and compressed to make tablets of approximately 6 mm diameter, both concave.

Example  34

Tablets each containing 75 mg of 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3-phthalimidopropionamide could be prepared by the following method:

Composition (for 1000 tablets)

3- (3-ethoxy-4-methoxyphenyl)-

N-hydroxy-3-phthalimido-

Propionamide ......... 75.0 g

Mannitol ......... 230.0 g

Lactose ............... 150.0g

Talc ........................ 21.0 g

Glycine ..... 12.5g

Stearic acid .......... 10.0g

Saccharin ......... 1.5g

5% gelatin solution ..... q.s.

All solid materials were first passed through a sieve having a 0.25 mm grid width. Mannitol and lactose were mixed and granulated by addition of gelatin solution, passed through a sieve with a 2 mm grid width, dried at 50 ° C. and passed through a sieve with 1.7 mm grid width. Carefully mix 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3-phthalimidopropionamide, glycine and saccharin, add mannitol, lactose grains, stearic acid and talc and add the whole The mixture was thoroughly mixed and pressed to make a tablet approximately 10 mm in diameter, with both grooves concave on top and with broken grooves on top.

Example  35

Tablets each containing 10 mg of N-benzyloxy-3- (3-ethoxy-4-methoxyphenyl) -3- (1-oxoisoindolinyl) propionamide could be prepared by the following method:

Composition (for 1000 tablets)

N-benzyloxy-3- (3-ethoxy-4-

Methoxyphenyl) -3- (1-oxoiso-

Indolinyl) propionamide ........................ 10.0 g

Lactose ......................... 328.5g

Corn starch ... 17.5 g

Polyethylene glycol 6000 ... 5.0 g

Talc ........................ 25.0g

Magnesium stearate .......... 4.0g

Demineralized water ..... q.s.

All solid materials were first passed through a sieve having a grid width of 0.6 mm. The active ingredient, lactose, talc, magnesium stearate and half starch were mixed immediately. The other half of starch was suspended in 65 mL of water and this suspension was added to a boiling polyethylene glycol solution in 260 mL of water. The resulting paste was added to the fine powdered material and, if necessary, water was added to make the mixture grainy. The grains were dried overnight at 35 ° C., passed through a sieve with a 1.2 mm grid width and compressed to make tablets approximately 10 mm in diameter, which had concave sides and broken v-shaped notches on top. .

Example  36

Gelatin dry-filled capsules each containing 100 mg of N-benzyloxy-3- (3-ethoxy-4-methoxyphenyl) -3-phthalimidopropionamide were prepared by the following method. Could prepare with:

Composition (for 1000 tablets)

N-benzyloxy-3- (3-cyclopentylidene-

Methyl-4-methoxyphenyl) -3-

Phthalimido-propionamide ... 100.0 g

Microcrystalline cellulose ....... 30.0 g

Sodium lauryl sulfate ............ 2.0g

Magnesium stearate ........ 8.0g

Sodium lauryl sulfate was sieved through N-benzyloxy-3- (3-ethoxy-4-methoxyphenyl) -3-phthalimidopropionamide through a sieve having a 0.2 mm grid width. Mix in detail for 10 minutes. Microcrystalline cellulose was then added through a sieve with a 0.9 mm grid width and the whole was again mixed in detail for 10 minutes. Finally, magnesium stearate was added through a sieve with a 0.8 mm grid width, and after mixing for an additional 3 minutes, the mixture was filled with 140 mg each into size 0 (stretched) gelatin dry-prepared capsules. .

Example  37

0.2% injection or infusion solutions can be prepared, for example, by the following method:

3- (3-cyclopentyloxy-

4-methoxyphenyl) -N-hydroxy-

3-phthalimidopropionamide ......... 5.0 g

Sodium chloride ........................ 22.5g

Phosphate buffer pH 7.4 ... 300.0 g

Demineralized water ............... to 2500.0 mL

3- (3-cyclopentyloxy-4-methoxyphenyl) -N-hydroxy-3-phthalimidopropionamide was dissolved in 1000 mL of water and filtered through a microfilter. Buffer solution was added and the whole was filled up to 2500 mL with water. To prepare a dosage unit form, 1.0 or 2.5 mL portions each were filled in glass ampoules (containing relatively 2.0 or 5.0 mg of imide, respectively).

Example  38

 3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxy -3- (3- Dimethylaminophthalimido ) Propionamide

3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (3-dimethylaminophthalimido) propionamide is a 3- (3-mg-87% yield) which is a yellow solid (280 mg, 87% yield). 3- (3-ethoxy-4-methoxyphenyl)-to yield 3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (3-dimethylaminophthalimido) propionamide Hydrogen of N-hydroxy-3- (3-dimethylaminophthalimido) propanoic acid (0.31 g, 0.75 mmol), carbonyldiimidazole (140 mg, 0.86 mmol) and tetrahydrofuran (5 mL) Prepared by the procedure of Example 1 from loxylamine hydrochloride (66 mg, 0.95 mmol): mp, 187.0-188.6 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.31 (t, J = 7.0 Hz, 3H, C H ₃ ), 3.01 (s, 3H, C H ₃ ), 3.08 (d, J = 7.9 Hz, 2H, C H ₂ ), 3.71 (s, 3H, C H ₃ ), 3.97 (q, J = 6.9 ㎐, 2H, C H ₂ ), 5.63 (t, J = 7.9 ㎐, 2H, C H ₃ ), 6.88 (br s, 2H, Ar), 7.00 (br s, 1H, Ar), 7.19 (m, 2H, Ar), 7.57 (dd, J = 7.1, 8.3 ㎐, 1H, Ar), 8.78 (br s, 1H, O H ), 10.57 (br s, 1 H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ 14.66, 34.42, 42.96, 49.88, 55.45, 63.72, 111.75, 112.41, 112.71, 113.74, 119.63, 122.32, 131.61, 133.94, 134.92, 147.60, 148.43, 149.75, 166.11, 166.11 , 167.56; Anal. Calcd for C ₂₂ H ₂₅ N ₃ O ₆ : C, 61.82; H, 5.89; N, 9.83. Found: C, 61.79; H, 5. 90; N, 9.58.

Example  39

3- (6,8- Dioxo (2H--1,3- Dioxolano [4,5-e] isoindolin -7-yl) -3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxypropionamide

3- (6,8-dioxo (2H--1,3-dioxolano [4,5-e] isoindolin-7-yl) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide is a 3- (6,8-dioxo (2H--1,3-dioxolano [4,5-e]) which is a greyish white solid (960 mg, 77% yield). 3- (6,8-dioxo (2H-1,3) to yield isoindolin-7-yl) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide -Dioxosolano [4,5-e] isoindolin-7-yl) -3- (3-ethoxy-4-methoxyphenyl) propanoic acid (1.20 g, 2.90 mmol), carbonyldiimidazole Prepared by the procedure of Example 1 from (517 mg, 3.19 mmol) and hydroxylamine hydrochloride (255 mg, 3.66 mmol) in tetrahydrofuran (8 mL): mp, 203.0 ° C .; ¹ H NMR (DMSO − d ₆ ) δ1.31 (t, J = 6.6 μs, 3H, C H ₃ ), 3.08 (d, J = 7.5 μs, 2H, C H ₂ ), 3.72 (s, 3H, C H ₃ ), 3.97 ( q, J = 6.9 ㎐, 2H, C H ₂ ), 5.62 (t, J = 7.3 ㎐, 1H, NC H ), 6.33 (s, 2H, C H ₂ ), 6.89 (br s, 2H, Ar), 6.99 (br s, 1H, Ar), 7.22 (dd, J = 7.7 ㎐ , 1H, Ar), 7.37 (d, J = 7.6 kPa, 1H, Ar), 8.80 (br s, 1H, O H ), 10.58 (br s, 1H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ14.67, 34.18, 50.12, 55.46 , 63.75, 104.31, 110.73, 111.76, 111.96, 112.37, 118.56, 119.62, 124.15, 131.25, 143.56, 147.66, 148.53, 154.12, 164.74, 165.99;. Anal Calcd for C 21 H ₂₀ N ₂ O ₈ + 1 H ₂ 0: C, 56.50; H, 4.97; N, 6.28. Found: C, 56.22; H, 4.63; N, 6.28.

Example  40

3- (3- Ethoxy -4- Methoxyphenyl ) -N- Hydroxy -3- (3,4- Dimethylaminophthalimido ) Propionamide

3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (3,4-dimethylaminophthalimido) propionamide is a white solid (430 mg, 84% yield) N-benzyloxy-3- (3-ethoxy- to yield-(3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (3-dimethylaminophthalimido) propionamide 4-methoxyphenyl) -N-hydroxy-3- (3-dimethylaminophthalimido) propanoic acid (0.63 g, 1.25 mmol), Pd (OH) ₂ / C (100 mg) and ethyl acetate Prepared by the procedure of Example 16 from hydrogen (50 psi) in methanol (30 mL each): mp, 197.0-202.5 ° C .; ¹ H NMR (DMSO-d ₆ ) δ1.31 (t, J = 7.2 Hz, 3H, C H ₃ ), 2.35 (s, 3H, C H ₃ ), 2.56 (s, 3H, C H ₃ ), 3.09 (d, J = 7.9 ㎐, 2H, C H ₂ ), 3.71 (s, 3H, C H ₃ ), 3.97 (q, J = 6.9 ㎐, 2H, C H ₂ ), 5.65 (t, J = 7.9 ㎐ , 2H, NC H ), 6.89 (br s, 2H, Ar), 7.00 (br s, 1H, Ar), 7.59 (br s, 2H, Ar), 8.78 (br s, 1H, O H ), 10.56 ( br s, 1 H, N H ); ¹³ C NMR (DMSO-d ₆ ) δ 13.22, 14.65, 19.33, 34.21, 49.88, 55.43, 63.72, 111.75, 112.40, 119.62, 120.39, 127.76, 129.33, 131.36, 134.71, 136.50, 142.13, 147.62, 148.48, 166.02 , 167.32, 168.65; Anal. Calcd for C ₂₂ H ₂₄ N ₂ O ₆ + 0.3 H ₂ 0: C, 63.24; H, 5.93; N, 6.70. Found: C, 63.11, H, 5.88; N, 6.67.

Example  40

Investigation of the pharmacological activity of the compounds of the present invention

The pharmacological activity of the compounds obtained in the above examples was investigated based on the method described in the detailed description of the present invention.

compound IC ₅₀ TNFα (μM) IC ₅₀ PDE4 (μM) % MMP2 inhibitory activity at 10 μM % MMP9 inhibitory activity at 10 μM 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (1-oxoisoindolinyl) propionamide 0.363 0.272 74.9 38.4 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (4-methylphthalimido) propionamide 0.0314 0.122 74.6 66.8 3- (3-cyclopentyloxy-4-methoxyphenyl) -N-hydroxy-3-phthalimidopropionamide 0.0237 0.0564 87 73.9 3- (3-cyclopentyloxy-4-methoxyphenyl) -N-hydroxy-3- (4-methylphthalimido) -propionamide 0.12 0.0966 64.6 82.2 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (1,3-dioxo-2,3-dihydro-1H-benzo [f] isoindol-2-yl) Propionamide 0.0596 0.271 85.2 74.9 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3-phthalimidopropionamide 0.115 0.051 82.4 82.3 N-hydroxy-3- (3,4-dimethoxyphenyl) -3-phthalimidopropionamide 0.84 0.708 93 79.8 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (3-nitrophthalimido) propionamide 11.1 0.103 18.5 17.5 N-hydroxy-3- {3- (2-propoxy) -4-methoxyphenyl} -3-phthalimidopropionamide 0.118 0.185 85.5 74.9 3- (4-aminophthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide 0.0451 0.036 95.1 46.3 N-hydroxy-3- (3,4-dimethoxyphenyl) -3- (1-oxoisoindolinyl) propionamide 1.23 2.31 77.1 46.3 3- (3-cyclopentyloxy-4-methoxyphenyl) -N-hydroxy-3- (1-oxoisoindolinyl) propionamide 0.101 0.133 73.8 46.9 3- (3-aminophthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide 0.0859 0.0545 48 43.4 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (4-hydroxyphthalimido) propionamide 0.249 0.0397 95.1 89.9 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (3-methylphthalimido) propionamide 3.12 0.121 36.4 31.8 3- (3-acetoamidophthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide 0.0874 0.0381 34.8 45.8 3- (4-acetoamidophthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide 0.219 0.038 89.2 80.8 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (1,3-dioxo-2,3-dihydro-1H-benzo [e] isoindol-2'-yl Propionamide 0.127 0.00995 N / D 74.2 3- (4-tert-butylphthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide 0.127 0.0177 0 66.4 3- (3,4-dimethoxyphthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydroxypropionamide 0.515 0.0789 0 87.8 3- (3-ethoxy-4-methoxyphenyl) -N-hydroxy-3- (3,4-dimethylaminophthalimido) propionamide 0.0454 0.0488 0 68.4

Alkanohydroxysamic acid derivatives, which are compounds of the present invention, have an excellent effect of reducing TNFα concentrations, and thus may be used for the treatment or prevention of various inflammatory, infectious, immune or malignant diseases of TNFα mediation.

The compounds of the present invention can also be used in the veterinary treatment of humans as well as other mammals in need of inhibition or prevention of TNFα production.

Claims (8)

Endotoxemia (endotoxomia), toxic shock syndrome (cachexia), adult respiratory distress syndrome (Adult) characterized in that it contains a compound of formula (a) or acid addition salts thereof as an active ingredient Respiratory Distress Syndrome, chronic pulmonary inflammatory disease, arthritis, hypercalcemia, graft versus host disease, cerebral malaria, asthma, inflammation, cancer, myocardial infarction, seizures, circulatory shock Pharmaceutical composition for treating any one disease selected from the group consisting of rheumatoid arthritis, viral infections and reperfusion injury:

... (a) here, R ¹ And R ² are each independently hydrogen, a lower alkyl group having 1 to 8 carbon atoms, or R ¹ and R ² are commonly combined with each other carbon atoms, o -phenylene group, o O- naphtylene, or cyclohexene-1,2-diyl, unsubstituted or nitro, cyano, or triplero Trifluoromethyl, carbetoxy, carbomethoxyoxy, carbopropoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, A carboxy group, a hydroxy group, an amino group, an alkylamino group having an alkyl group having 1 to 8 carbon atoms, a dialkylamino group having an alkyl group having 1 to 8 carbon atoms, an alkyl group of an acyl group Is an acylamino group having 1 to 8 carbon atoms, alkyl having 1 to 10 carbon atoms (Alkyl), it is a (substituted) alkoxy group (alkoxy) and halogen (halo) 1 ~ 4 substituents (substituents) each independently selected from the group consisting of having 1 to 10 carbon atoms; R ³ has a nitro group, a cyano group, a trifluoromethyl group, a carbetoxy group, a carbopropoxy group, an acetyl group, a carbamoyl group, an acetoxy group, a carboxy group, a hydroxyl group, an amino group, and having 1 to 10 carbon atoms Alkyl group, alkoxy group having 1 to 10 carbon atoms, cycloalkoxy having 3 to 6 carbon atoms, C ₄ -C ₆ -cycloalkylidenemethyl group (C ₄ -C ₆ -cycloalkylidenemethyl), C _3- A C ₁₀ -alkylidenemethyl group (C ₄ -C ₆ -alkylidene methyl), an indanyloxy group and a phenyl group substituted with 1 to 4 substituents selected from the group consisting of a halogen group; R ⁴ is hydrogen, an alkyl group having 1 to 6 carbon atoms, a phenyl group or a benzyl group; R ^{4 '} is hydrogen or an alkyl group having 1 to 6 carbon atoms; R ⁵ is —CH ₂ —, —CH ₂ —CO, —CO—, —S0 ₂ —, —S— or —NHCO—; n is 0, 1 or 2. The pharmaceutical composition of claim 1, wherein the disease is cancer. The pharmaceutical composition of claim 1, wherein the disease is inflammation. The pharmaceutical composition of claim 1, wherein the disease is a chronic pulmonary inflammatory disease. The pharmaceutical composition of claim 1, wherein the disease is asthma. The pharmaceutical composition of claim 1, wherein the disease is rheumatoid arthritis. The pharmaceutical composition of claim 1, wherein the disease is cachexia. 8. The compound of claim 1, wherein the compound is 3- (3-acetoamidophthalimido) -3- (3-ethoxy-4-methoxyphenyl) -N-hydric. Pharmaceutical composition, characterized in that oxypropionamide.